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Abstract 
 
 
Umbilical cord matrix or Wharton’s Jelly is a mucous connective tissue 
ensheathing the cord blood vessels and contains mesenchymal-like stem cells.  
Previously, we have shown that pig umbilical cord matrix stem (pUCMS) cells 
transplanted into normal rat brain were recovered up to 6 weeks post-
transplantation, where a sub-population of pUCMS cells exhibited neuronal 
morphology and expressed a variety of neuronal markers.  Here, approximately 
150 pUCMS cells were transplanted into non-immunesuppressed rats that 
previously received a brain lesion by neurotoxin, 6-hydroxydopamine (6-OHDA), 
which specifically affects midbrain dopaminergic neurons, leading to pathologic 
findings similar to that of Parkinson’s disease (PD).  The pUCMS cells 
proliferated up to 8 weeks post-transplantation and there was a significant 
increase in the percentage and number of pUCMS cells expressing tyrosine 
hydroxylase (TH), which is a marker for dopaminergic cells.  We conclude that 1. 
Xenotransplants of pig UCMS cells are not rejected by rats at least up to 8 weeks 
after transplantation and 2. The pig UCMS cells proliferate and differentiate after 
transplantation into PD model rats.  
 
The surface antigen and gene expression profile of human umbilical cord matrix 
stem (hUCMS) cells resemble that of mesenchymal stem cells.  Apomorphine-
induced rotatory behavior was used to analyze the motor deficits of the PD model 
rats.  In different experiments 1000, 2500 and 25000 hUCMS cells were 
transplanted into the brain of non-immunesuppressed PD model rats.  There was 
 3 
a dose-dependent decrease in apomorphine-induced rotations; the maximum 
benefit was found in the rats that received 1000 hUCMS cells.  The graft cells 
were recovered at 2 days and 1 week, but not at 6, 10 or 12 weeks post-
transplantation.  Quantitative assessment of host TH-positive midbrain 
dopaminergic neurons revealed a positive correlation between the behavioral 
improvement and TH-positive cell number in the low-density (1000 cells) 
transplant group, showing that the hUCMS cells may play a role in rescuing 
damaged host dopaminergic neurons and promote improvement of motor deficits 
in PD-model rats.  In summary, hUCMS cells appear to be mesenchymal stem 
cells that can be harvested in great numbers from a non-controversial, 
inexhaustible source.  Human UCMS cells show therapeutic benefit in PD model 
rats, but the mechanism by which they promote improvement is presently 
unknown.   
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BACKGROUND AND SIGNIFICANCE 
 
PARKINSONS DISEASE 
Parkinsons disease (PD) is a chronic, progressive neurodegenerative disease of 
the central nervous system that belongs to a group of conditions called as 
movement disorders.  PD was first described in 1817 by Dr. James Parkinson, a 
London physician, who described the disease as ‘Shaking Palsy’.  The 
degeneration of neurons in this disease is largely limited to dopaminergic (DA) 
neurons in substantia nigra (SN) and ventral tegmental area (VTA) of the 
midbrain, and their projections to the forebrain, leading to the deficiency of 
neurotransmitter, dopamine (see figure 1.1).  Dr. Arvid Carlsson, who was a 
leader in the development of these ideas, has won a Nobel prize for his valuable 
contributions.  The primary symptoms of PD are motor symptoms: muscle rigidity 
– stiffness of muscles, resting tremor – trembling at rest, and bradykinesia – 
slowness of movement (Lang and Lozano, 1998b;Lang and Lozano, 1998a).  
Figure 1.2A shows the normal circuitry that involves the midbrain DA neurons 
and their projections to the forebrain, and figure 1.2B indicates the hypokinetic 
changes in the circuitry that lead to the motor symptoms in PD.  As the disease is 
progressive, the symptoms become worse with time involving multiple 
neurotransmitter systems (Beal, 2001).  Although there are exceptions of early 
onset, the symptoms in PD generally appear late, in the fifth or sixth decade of 
life.  An estimated 1.5 million Americans suffer from PD, with an estimated 60, 
000 new cases diagnosed each year. 
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Figure 1.1 Illustration of nigrostriatal tract in parasagittal section of a rat brain:  
 
Midbrain dopaminergic (DA) neurons in substantia nigra (SN) and ventral 
tegmental area (VTA) and their axonal projections to striatum (caudate nucleus 
and putamen), globus pallidus, and thalamus, constitute the nigrostriatal 
pathway, which is mainly affected in Parkinson’s disease. 
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Approximately 5 years before the development of the symptoms, the levels of 
dopamine in SN are significantly reduced suggesting that the symptoms develop 
only after a threshold is reached.  The major neuropathologic findings in PD are 
loss of DA neurons in ventral midbrain and presence of Lewy bodies (mis-folded 
protein aggregates).  The loss of DA neurons is also seen in normal individuals, 
where there is a steady decrease of about 4% per decade beginning at about the 
age of 20.  Based on the etiology, there are two forms of PD; sporadic and 
familial (see figure 1.3).  The normal age-dependent loss as well as death of DA 
neurons in both forms of PD is thought to be due to oxidative stress (Beal, 
2003b;Dawson and Dawson, 2003;Zhang et al., 2000).  In PD, there is a clear 
evidence of oxidative stress in the following situations: glutathione depletion – 
one of the primary antioxidants, iron deposits – impairs the ability of the cells to 
detoxify hydrogen peroxide, lipid peroxidation, oxidative damage to DNA 
(mitochondria), protein nitration, and decreased mitochondrial function (Dawson 
and Dawson, 2003;Zhang et al., 2000;Beal, 2003b).  This may be due to an 
increase in the production of free radicals as well as decreased detoxification.  
As the level of MAO-A (mono amino oxidase – A) is high in DA neurons, they 
produce high amount of hydrogen peroxide, and thus any compromise in the 
oxidative state will lead to toxicity. 
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Figure 1.2 Normal and Hypokinetic circuitry in Parkinson’s disease 
A. Normal circuitry (connections) in the corto-basal ganglia loop. 
B. Abnormal hypokinetic motor loop in Parkinson’s disease. 
GABA: γ-aminobutyric acid, SMA: smooth muscle afferents, PMC: peripheral 
muscle contractions.  Neurotransmitters are indicated in blue. 
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A large number of PD cases are identified as sporadic form, with environmental 
causes being implicated, but additional genetic involvement has been identified 
as a predisposing factor (Dawson and Dawson, 2003;Zhang et al., 2000).  An 
example of an environmental cause, which has been well documented, is the 
toxicity of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyrodine) – a synthetic 
heroin analog.  MPTP induces irreversible and severe motor abnormalities that 
are similar to that of PD (Beal, 2001).  A neurotoxin, 6-hydroxydopamine (6-
OHDA) selectively accumulates in DA neurons, and it then kills these neurons 
primarily owing to oxidative stress as described above (Beal, 2003b;Beal, 
2001;Kim et al., 2002).  Selectivity of DA neurons appears to be due to high 
affinity of these toxins for dopamine transporters, and once inside the neuron 
they act by inhibiting the mitochondrial complex I, resulting in energy failure and 
increased formation of superoxide anion (Beal, 2004;Beal, 2003a).  Most of the 
toxicity due to superoxide anion is believed to be due to its reaction with other 
reactive oxygen species such as nitric oxide (NO), resulting in a potent oxidant 
peroxynitrate, which has been implicated in many neurologic diseases.  It has 
been shown that transgenic mice which over express superoxide dismutase 
(SOD-1) were more resistant to toxin-induced DA neurotoxicity (Przedborski et 
al., 1992). 
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Figure 1.3 Pathogenesis of Parkinson’s disease (modified from Lotharius, 2002) 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrodine  
6-OHDA: 6-hydroxydopamine.   
Although different etiological factors lead to sporadic and familial forms of 
Parkinson’s disease, all the different pathways may result in oxidative stress and 
followed by neurodegeneration.  
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In 1997 the gene for one form of inherited PD was identified and the protein was 
identified as α-synuclein, which is located on chromosome 4 and belongs to a 
family of structurally related proteins that are prominently expressed in the CNS. 
Mutations in α-synuclein (A53T and A30P) cause autosomal dominant familial 
PD (Lotharius and Brundin, 2002b;Lotharius and Brundin, 2002a).  After the 
identification of α-synuclein gene, the protein was identified as a component of 
Lewy bodies.  It has also been shown that the α-synuclein in the Lewy bodies is 
nitrated, which is a clear indication that the cells are experiencing oxidative 
stress.  A second gene for PD, Parkin, was identified in 1998 and is located on 
chromosome 6, and causes autosomal recessive juvenile parkinsonism (AR-JP) 
(Dawson and Dawson, 2003;Lotharius and Brundin, 2002b).  Mutations in other 
gene, UCH-L1, which affect the ubiquitin proteosome pathway that helps in 
degradation of protein aggregates, have been reported to cause autosomal 
dominant PD (Dawson and Dawson, 2003).  The interaction of these three genes 
and their role in PD is illustrated in figure 1.3. 
 
Symptomatic treatments such as, drugs that replace dopamine and specific 
surgeries (Obeso et al., 2000),  are currently used to reverse the symptoms of 
PD, but a therapeutic agent to prevent or cure PD is yet to be discovered.  The 
current (symptomatic) and future therapeutic strategies for PD are listed in figure 
1.4.  The future therapeutic interventions in PD primarily include the replacement 
and rescue strategies (fig 1.4), which shows that stem cells can be used to 
replace or rescue the damaged DA neurons in PD. 
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Figure 1.4 Current (symptomatic) and future therapeutic strategies for 
Parkinson’s disease. 
The current (symptomatic) therapy for Parkinson’s disease (PD) is mainly 
targeted to replace the dopamine or surgically manipulate/stimulate specific brain 
areas to modulate the motor deficits of PD.  The future therapeutic strategies 
including the stem cell therapy is targeted to either replace or rescue damaged 
dopaminergic neurons. 
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STEM CELLS 
Stem cells are defined as a population of primitive undifferentiated cells, which 
are capable of self-renewal and differentiate into multiple cell or tissue types.  
Figure 1.5 illustrates various sources of human stem cells.  Embryonic stem cells 
(ESCs), which are derived from the inner cell mass of the blastocyst (Evans and 
Kaufman, 1981), are pluripotent cells, meaning that they can give rise to cell-
types of all the three germlayers (ectoderm, endoderm and mesoderm) in the 
embryo (Nagy et al., 1990;Nagy et al., 1993).  Although there are additional 
markers, the markers listed in table 1.1 are commonly used to identify pluripotent 
stem cells.  Among the markers listed in table 1.1, Oct-4, Sox-2 and Nanog are 
often considered as standard markers for undifferentiated pluripotent stem cells.  
However, it has been shown that stem cells that do not express all the 
pluripotency markers may still have the potential to give rise to cells/tissues of all 
the three germ layers, thus proving their pluripotency (Jiang et al., 2002a).  ESCs 
that can generate terminally differentiated neuronal and glial cells could provide 
an unlimited source of these cells, which can be used for replacement therapy in 
various neurodegenerative diseases.  Embryonic germ cells (EGCs) are 
pluripotent stem cells that can be harvested from a developing embryo (See 
figure 1.5), and were shown to have the potential of differentiating into neurons in 
vitro (Pan et al., 2005;Park et al., 2004;Turnpenny et al., 2005).  Embryonic 
carcinoma (EC) cells, derived from tumors called teratocarcinomas, are 
pluripotent stem cells  that are known to be as malignant counterparts of ESCs 
(Przyborski et al., 2004).  Teratocarcinomas are thought to originate from  
 11 
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Figure 1.5 Sources of human stem cells 
 
 
Totipotent: potential to form any cell/tissue type in the embryo including 
extraembryonic membranes. 
Pluripotent: potential to form any cell/tissue type in the embryo, but not 
extraembryonic membranes. 
Multipotent: potential to form cell/tissue type of more than one germ layer, but not 
all. 
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transformed germ cells and are observed in both young and adult individuals.  
Human EC cells were suggested to be useful as a model to study human 
development (Przyborski et al., 2004).  Previously, it has been shown that EC 
cells are capable of differentiating into neurons in vitro (Pleasure and Lee, 1993).   
 
Although they are described as fetal stem cells, neural stem cells (NSCs) are 
immature, uncommitted cells that exist in both the developing and adult brain 
(Morrison et al., 1997;Palmer et al., 1997;Armstrong and Svendsen, 
2000;Svendsen and Caldwell, 2000).  NSCs can be expanded in vitro and 
differentiated into neuronal and glial cells in vitro (Reynolds and Weiss, 
1992;Vescovi et al., 1993) and in vivo (Armstrong et al., 2000;Ostenfeld et al., 
2000).  However, adult NSCs in the central nervous system require an invasive 
procedure to obtain, and have a limited potential of expansion in vitro.  Different 
types of neuronal and glial cells that can be obtained from NSCs can be useful 
for replacement therapy in various neural diseases (Armstrong and Svendsen, 
2000).  Similar to NSCs, hematopoietic stem cells (HSCs) can be extracted from 
fetal and adult tissues.  Although bonemarrow is the classic source, umbilical 
cord blood is a rich source of HSCs.  Transplantation of HSCs is shown to be 
effective in treating many metabolic diseases and malignancies (Consolini et al., 
2001;Mayhall et al., 2004;Wright-Kanuth and Smith, 2001).  In addition, it has 
been shown that HSCs may play a role in repairing the neural tissues in 
traumatic and ischemic brain damage and neurodegenerative diseases (Nan et 
al., 2005;Newman et al., 2004;Sanchez-Ramos et al., 2000). 
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Transcription factor essential for establishment and maintenance of 
undifferentiated PSCs
Oct-4
SignificanceMarker
 
 
 
Table 1.1 Typical markers to identify undifferentiated pluripotent stem cells 
(PSCs) 
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Bone marrow stromal cells (BMSCs), which are a type of mesenchymal stem 
cells, are harvested from fetal or post-natal or adult sources.  Previous studies 
have indicated that BMSCs can be expanded in culture to a limited extent and 
give rise to multiple cell-types of mesodermal origin (Pittenger et al., 
1999;Prockop et al., 2001).  BMSCs were shown to be capable of differentiating 
into neural cells in vitro (Sanchez-Ramos et al., 2000;Woodbury et al., 2000), 
and in vivo following transplantation into rodents (Kopen et al., 1999).  Another 
type of adult stem cell that raised public interest is the multipotent adult 
progenitor cell (MAPC), which is isolated from bone marrow (Reyes and 
Verfaillie, 2001).  Recent studies with MAPCs have shown that they are 
pluripotent and can be extracted from muscle and brain in addition to bone 
marrow, suggesting that MAPCs may be involved in plasticity (capability of 
regeneration) of various adult tissues (Jiang et al., 2002b;Jiang et al., 2002a).   
 
Whether the post-natal and adult stem cells are undifferentiated stem cells that 
can differentiate into other cell types, or they are differentiated cells that have the 
capability to form other cell types, has been an interesting debate among various 
research groups.  Although it is contentious, the differentiation capability of post-
natal and adult stem cells is attributed to various mechanisms, such as 
transdifferentiation, dedifferentiation and cell-fusion (Shen et al., 2003;Tosh and 
Slack, 2002).  Transdifferentiation is described as conversion of one 
differentiated cell type into other, for example, BMSCs were shown to 
differentiate into a neural cells (Woodbury et al., 2000).  Dedifferentiation is 
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progression of cells from a more differentiated to less differentiated or progenitor 
state, for example, during regeneration of the lens fibers in the eye, pigment 
epithelial cells were shown to dedifferentiate into intermediate progenitor cells 
before differentiating into lens fibers (Burke and Tosh, 2005).  Cell-fusion is a 
phenomenon where donor stem cells fuse with the resident cells and differentiate 
or attain the phenotype of the recipient cells, for example, bone marrow cells 
have been shown to fuse spontaneously with ESCs in vitro to attain the 
phenotype of the recipient cells (Terada et al., 2002).  However, dedifferentiation 
and cell-fusion are sometimes considered as a part of transdifferentiation.   
 
Stem cells, with their unique ability of self-renewal and differentiation, may have 
a great potential to be used as therapeutic agents in various debilitating diseases 
including neurological diseases.  For example, ESCs, which are immortal (have 
the capability of indefinite self-renewal) and pluripotent (Dinsmore et al., 
1996;Lee et al., 2000;Thomson et al., 1998a;Thomson et al., 1998b) have been 
shown to be beneficial in various disease models (Auerbach et al., 2000;Johkura 
et al., 2003;McDonald et al., 1999).  However, each of the well documented stem 
cell types has its own limitations: the moral and ethical concerns of harvesting 
and using ESCs, difficulty in maintaining ESCs in culture and problems 
associated with their transplantation, difficulty in maintenance and expansion of 
neural stem cells, difficulty in expansion and limited use of HSCs for 
transplantation into a heterogeneous tissue or a mismatched individual.  
Although some EC cells were shown to be phenotypically similar to ESCs and 
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exhibit pluripotency, their basic malignant nature, altered genotype (Duran et al., 
2001) and inconsistent differentiation potential are major limitations for these 
cells to be used for research and clinical purposes.  The various limitations 
associated with the established stem cell types emphasize the importance of 
exploring and evaluating other sources of stem cells.  For example, adult stem 
cells from bone marrow have been shown to be multipotent or pluripotent (Jiang 
et al., 2002b;Jiang et al., 2002a;Schwartz et al., 2002).  Other sources of post-
natal and adult stem cells, such as skin, liver, muscle, intestine, adipose tissue 
etc., have been reported (Safford et al., 2004;Dotto and Cotsarelis, 2005;Tang, 
2005;Bjerknes and Cheng, 2005). 
 
STEM CELL THERAPY IN PARKINSON’S DISEASE 
Although PD animal models do not show similar symptoms as seen in human 
patients, the pathology and related motor deficits seen in these animals provide a 
good model to evaluate various therapeutic agents including stem cells.  Drug-
induced rotatory behavior is an easily quantifiable motor deficit that is often used 
to evaluate the behavioral improvement in the rodent PD models (Beal, 2001).  
Figure 1.6 shows an illustration of an experimental model to test the potential of 
stem cells in promoting behavioral recovery in PD model rats.  As mentioned 
earlier, stem cells can be used for replacement or rescue of DA cells in PD (see 
figure 1.7).  Ventral midbrain cells from human fetus that are transplanted into the 
striatum of PD model animals have resulted in functional recovery by restoring 
DA neurotransmission (Lindvall et al., 1990).   Cells derived from the fetal 
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midbrain can modify the course of neurodegenerative diseases, but they are 
inadequate source of dopamine synthesizing neurons because their ability to 
generate these neurons is unstable (Brundin et al., 2000).  Ventral midbrain cells 
obtained from fetal pigs were used for therapeutic transplantation in PD patients, 
which is not yet approved for clinical purposes (Bjorklund and Lindvall, 
2000;Deacon et al., 1997).  In addition, a major concern with xenotransplantation 
is graft versus host disease (GVHD) and immune rejection (Larsson et al., 2000).  
Although immunesuppression increases the survival of transplanted cells 
(Deacon et al., 1997), it was estimated that only 5-10% (Bjorklund, 1991) or 
about 25% (Brundin et al., 2000) of the harvested cells survive transplantation.   
Moreover, serious complications (nephrotoxicity, cardiovascular toxicity, 
neurotoxicity, etc.) can arise as secondary effects of the immunosuppressive 
drugs, such as cyclosporine-A (Li et al., 2004;Rezzani, 2004;Serkova et al., 
2004;Miller, 2002).  Although adult CNS stem cells can be expanded and 
differentiated into dopaminergic (DA) neurons, these are tough to harvest and 
have only a limited ability to expand in vitro and to adopt a dopaminergic fate 
(Gage et al., 1998;Gage et al., 1995).   
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Stem cell
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rotatory behavior
 
 
Figure 1.6 Experimental model to evaluate the effect of stem cell therapy in a 
Parkinson’s disease (PD)-model rat. 
MFB: medial forebrain bundle (projections of dopaminergic neurons) 
6-OHDA: 6-hydroxydopamine, SN: substantia nigra, VTA: ventral tegmental area. 
Parkinson’s disease model rats can be created by injecting a neurotoxin, 6-
OHDA, into the nigrostriatal pathway (either in the dopaminergic neurons in SN 
and VTA or their projections).  Drug-induced rotatory behavior can be quantified 
and followed over time after stem cell transplantation to evaluate the potential of 
stem cells to promote behavioral recovery.  Further, histological analysis of the 
rat brain would elaborate on the potential of stem cells to replace or rescue 
damaged DA neurons in the PD model rat. 
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Embryonic stem cells (ESCs) can be expanded in vitro and differentiated into DA 
neurons both in vitro and in vivo (Morizane et al., 2002;Kim et al., 2002;Lee et al., 
2000).  The DA neurons derived from ESCs have been shown to promote 
therapeutic benefit in PD model rats and mice (Kim et al., 2002;Nishimura et al., 
2003).  When small numbers (1000-2000 cells) of undifferentiated ESCs were 
transplanted to rat striatum, they proliferate and differentiate into DA neurons 
(Bjorklund et al., 2002).  Dopamine neurons derived from ESCs function in an 
animal model of PD (Bjorklund et al., 2002;Nishimura et al., 2003).  The 
problems with transplanting ESCs are formation of teratomas (due to 
uncontrolled proliferation) and immune rejection.  Although NSCs and ESCs 
have been big contenders for replacement therapy, adult stem cells such as 
BMSCs were reported to be a potential source of replacement cells  that can 
promote the desirable therapeutic effect in the PD animal models (Dezawa et al., 
2004).  In addition, stem cells that were genetically engineered to enhance DA 
neuronal differentiation have been shown to be effective in rescuing PD model 
animals (Kim et al., 2002;Chung et al., 2005).  Thus, the ideal characteristics of 
cell grafts for replacement therapy would be, 1. The capacity to engraft and 
differentiate into the appropriate replacement cells, 2. The ability to not stimulate 
a robust immune rejection response, 3. Non-tumorigenic, 4. Non-controversial 
and 5. Economic feasibility. 
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Figure 1.7 Applications of stem cells in Parkinson’s diseases 
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Recently, neuroprotective strategies to regenerate/rescue damaged neurons 
have received much attention.  As PD is characterized by progressive 
degeneration of DA neurons, it may be possible to intervene the degeneration 
process to rescue and revitalize the cells.  It has been reported that some stem 
cells may have an inherent ability to rescue damaged neurons by releasing 
neurotrophic factors (Ourednik et al., 2002;Borlongan et al., 2004).  In addition, 
the use of stem cells to deliver neurotrophic factors as well as non-pathogenic 
viral vectors as gene delivery vehicles (to increase the expression of 
neurotrophic factors) has been developed and tested on animal models of PD 
(Bjorklund and Lindvall, 2000;Bjorklund, 1991;Bjorklund et al., 2000).  According 
to Dr. Ron D. McKay, “Cells are the ultimate device for delivering substances to 
the brain, so this could become one of the most widely used therapies in medical 
research (1998).”  Stem cells that are genetically engineered ex vivo with specific 
therapeutic molecules are capable of delivering those substances effectively to 
the desired target (Yoshimoto et al., 1995;Lu et al., 2005).  For example, it has 
been shown that mesenchymal stem cells engineered with tyrosine hydroxylase 
(TH – rate limiting enzyme in dopamine synthesis) show therapeutic benefit in 
PD model rats by restoring the dopamine levels in the striatum (Lu et al., 2005).  
Glial cell line derived neurotrophic factor (GDNF) is a neurotrophic factor that has 
been shown to rescue damaged DA neurons in vitro and in vivo (Arenas et al., 
1995;Ding et al., 2004).  GDNF has been used to rescue PD animal models 
through genetically engineered stem cells that produce GDNF or non-pathogenic 
viral vectors containing GDNF transgene (Bjorklund et al., 1997;Bjorklund et al., 
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2000;Kirik et al., 2000a;Kirik et al., 2000b).  In both approaches substantial 
prevention of neurodegeneration was observed.  However, the recent clinical trial 
in humans with GDNF has been discontinued for unknown reasons.   
 
In addition to the rescue mediated by neurotrophic factors, it has been reported 
that stem cells can mediate regeneration of neural tissue by immune modulation 
(Pluchino et al., 2005b;Pluchino et al., 2005a).  As it has been shown previously 
that immune cells may play a role in PD (Block and Hong, 2005;Wu et al., 
2005;Zhang et al., 2005), it is possible that the immune modulatory effects of 
stem cells may be useful to promote therapeutic benefit in PD.  Recently, it has 
been shown that mesenchymal stem cells possess immunosuppressive 
capabilities (Djouad et al., 2003;Ryan et al., 2005), which may play a direct role 
in promoting rescue of the damaged neural tissue or they may play an indirect 
role as co-grafts with other replacement cell type and modulate the immune 
response and facilitate engraftment and differentiation of the replacement cell (Le 
and Ringden, 2005a;Le and Ringden, 2005b).  This approach of neuroprotection 
to regenerate/rescue damaged neurons might lead to other interesting therapy 
for neurodegenerative diseases as well as suggesting a fundamental change in 
some of our concepts in neurobiology about the brain.  In addition to the 
replacement and rescue from transplanted stem cells, it has been reported that 
endogenous stem cells in the brain can be recruited to the site of repair and 
contribute to either replacement or rescue of the damaged cells (Ferretti, 2004). 
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UMBILICAL CORD MATRIX STEM CELLS 
Umbilical cord is a flexible cord-like structure found in amniotes.  In placental 
mammals, umbilical cord connects the fetus to its placenta (tissue that connects 
fetus to the uterus and mediates the exchange of nutrients, oxygen, hormones, 
and waste products throughout the pregnancy).  The umbilical cord primarily 
comprises umbilical vessels and supporting connective tissue (Figure 1.8 shows 
the H&E stained cross section of human umbilical cord showing two arteries and 
a vein surrounded by connective tissue).  In addition, the umbilical cord may 
contain the remnants of yolk sac (omphalomesenteric duct) and allantois 
(urachus).  The umbilical vessels are formed by the extraembryonic mesoderm 
that connects the embryo to the trophoblast (outermost layer of cells of blastocyst 
that helps in implantation of early embryo in the uterine wall).  Although the origin 
of the connective tissue that supports these umbilical vessels is unclear, it closely 
resembles mesenchyme, an embryonic tissue of mesodermal origin that is 
characterized by a loose aggregation of cells surrounded by extracellular matrix. 
The extracellular matrix contains abundant collagen and glycosaminoglycans 
(GAGs), mainly hyaluronic acid, which constitutes 70% of the total GAGs 
(Bankowski et al., 1996). 
 
Umbilical cord was once regarded as a biological waste and discarded after the 
fetus is delivered.  Collection of umbilical cord blood in mid-20th century to isolate 
hematopoietic mononuclear cells has ascertained importance to this tissue, 
which is followed by reports of various types of stem cells being harvested from 
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the umbilical cord.  It has been shown that umbilical cord blood is a source of 
HSCs (Consolini et al., 2001;Wright-Kanuth and Smith, 2001) and mesenchymal 
stem cells (Kogler et al., 2004;Sanberg et al., 2005).  In addition, it has been 
reported that umbilical cord blood may be used to treat various diseases 
including neural disorders (Wright-Kanuth and Smith, 2001;Borlongan et al., 
2004;Nan et al., 2005;Newman et al., 2004).  Several labs have reported 
mesenchymal stem cells that are pluripotent or multipotent from various parts of 
the umbilical cord (Sarugaser et al., 2005;Kogler et al., 2004;Lee et al., 2004).  
Although stem cells from umbilical cord are regarded as post-natal stem cells, 
the fact that umbilical cord is formed much earlier during embryonic development 
(fig 1.5 shows umbilical cord in a 4 week human embryo) shows that it may be a 
source of more primitive cells.  In addition, it has been shown that fetal HSCs and 
mesenchymal stem cells exhibit more primitive stem cell characters than their 
adult counterparts (Gotherstrom et al., 2005;Huang et al., 1998).  During 
development, primitive stem cells, such as EGCs and HSCs migrate from the 
secondary yolk sac region through the umbilical cord region to the embryo.   
 
The umbilical cord matrix (UCM) or Wharton’s jelly is a completely different part 
of the umbilical cord than cord blood that is collected from the umbilical vessels.  
The UCM is a mucous connective tissue of umbilical cord that encircles the 
umbilical vessels and consists of myofibroblast-like stromal cells, collagen fibers 
and proteoglycans (Kobayashi et al., 1998;McElreavey et al., 1991).  In addition,  
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Figure 1.8 H&E stained cross-section of human umbilical cord 
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UCM has been identified as a source of growth-regulatory factors that are 
constitutively produced by the UCM cells (Irvine et al., 1984).  UCM is a source of 
post-natal stem cells that, in contrast to other sources, is amenable to rapid 
isolation of large numbers of cells.  Moreover, the cells can be harvested non-
invasively from this inexhaustible and non-controversial source.   
 
The pig umbilical cord matrix stem (pUCMS) cells exhibit stem cell characteristics 
and can be differentiated into neural-like cells that express neural and glial 
markers in vitro (Mitchell et al., 2003).  Two to six weeks following transplantation 
into rat brain, a subset of pUCMS cells were found to morphologically resemble 
neurons and express pig-specific neuronal markers (Weiss et al., 2003).  In 
addition, cells were isolated from the human umbilical cord matrix (hUCM) that 
can be expanded in culture and respond to in vitro neural differentiation signals 
(Mitchell et al., 2003).  Recently, other labs were able to harvest multipotent 
mesenchymal stem cells from Wharton’s jelly (Wang et al., 2004) and reported 
that these cells from the umbilical cord matrix may have therapeutic potential in 
PD (Fu et al., 2005).  Moreover, mesenchymal stem cells from bone marrow 
have been shown to be capable of differentiating into neurons in vitro and in vivo 
and exhibit immunosuppressive capabilities, and thus may be useful in treating 
PD either by replacement or rescue of damaged DA cells (Dezawa et al., 
2004;Prockop et al., 2001;Woodbury et al., 2000).  These UCMS cells are non-
controversial and inexhaustible stem cell source that may be useful to treat 
neurodegenerative disorders, such as PD. 
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Abstract 
Previous work indicated that pig umbilical cord matrix (pUCM) cells are a type of 
primitive stem cell and that these cells could be recovered after central or 
peripheral injection into rats that did not receive immune suppression therapy.  
To determine the safety and proliferation potential of pUCM cells after brain 
transplantation, approximately 150 pUCM cells were transplanted into the brains 
of rats that previously received a striatal injection of the neurotoxin 6-
hydroxydopamine (6-OHDA).  The pUCM cells were previously engineered to 
express enhanced green fluorescent protein (eGFP); in this way the graft cells 
were identifed.  The rats did not receive immune suppression therapy.  There 
were no post-surgical complications and the animals thrived following 
transplantation.  At 2, 4, 6, and 8 weeks after transplantation, two rats were 
sacrificed and the morphology, size and number of graft cells and the percentage 
of tyrosine hydroxylase (TH)-positive graft cells was determined.  The size 
distribution of the grafted pUCM cells was unimodal and normal and the average 
size increased significantly over the 2-8 week survival period. The number of 
pUCM cells increased from approximately 5,400 cells at the 2 week survival 
period post-transplantation to approximately 20,000 cells at the 8 week survival 
period.  There was an increase in the percentage of TH-positive pUCM cells from 
approximately 1% at the 2 week survival period to approximately 6% at the 8 
week survival period.  There was no evidence of a significant host immune 
response at any time e.g. no accumulation of CD-4, CD-8, CD-11b, CD-161 cells 
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in the transplantation site. These results suggest that pUCM cells engraft and 
proliferate without requiring immune suppression. These findings also suggest 
that a subset of pUCM cells can differentiate into TH-positive cells within 8 weeks 
after transplantation into the 6-OHDA lesioned rat brain.  
 
 
Keywords:  umbilical cord matrix, green fluorescent protein, tyrosine hydroxylase, 
Wharton’s jelly, xenotransplantation, 6-hydroxydopamine brain lesion 
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Introduction 
In Parkinson’s disease (PD), human fetal mesencephalic transplants were once 
used as a source of replacement cells.  Moral / ethical concerns associated with 
the use of fetal tissue, the scarcity of that tissue and other problems associated 
with obtaining enough tissue were barriers to the widespread use of human fetal 
mesencephalic transplantation.  Mesencephalic cells obtained from fetal pigs are 
one treatment modality used for therapeutic transplantation in PD patients, which 
is yet to be approved for clinical purposes [2;7].  Xenotransplantation has 
problems such as graft versus host disease (GVHD) and immune rejection [13].  
For therapeutically useful numbers of the xenografted cells to survive, the host's 
immune system must be suppressed [7].  Despite immune suppression, it was 
estimated that about 5-10% [1] or about 25% [5] of the harvested cells survive 
transplantation.  Experimental work with fetal pig mesencephalic tissue grafted 
into the rat brain indicates that the grafted tissue is rejected in about 4-6 weeks 
[14].  The rejection response affects the function of the engrafted tissue because 
the grafts with a lower immune rejection response have better survival and more 
extensive fibers compared to animals with stronger immune rejection response 
[14].  Furthermore, immunosuppression treatment slows but does not prevent the 
rejection of pig tissue grafts in rat brain [8].  At the same time serious 
complications can arise from immunosuppression and from the secondary effects 
of the immunosuppressive drugs, such as cyclosporine-A.   Thus, two ideal 
characteristics of therapeutic grafts would be 1) the capacity to treat the 
neurodegenerative disease, i.e., differentiate into the appropriate replacement 
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cells or produce factors that slow or reverse the disease process and 2) the 
ability to not stimulate a robust immune rejection response. 
 
The umbilical cord matrix, or Wharton’s jelly, is a gelatinous connective tissue of 
umbilical cord, which consists of myofibroblast-like stromal cells, collagen fibers 
and proteoglycans [12;18].  The umbilical cord matrix is a source for primitive 
stem cells and differentiation signals cause pUCM cells to exhibit a neuronal 
morphology and express neural and glial markers in vitro [19].  Two to six weeks 
following transplantation into rat brain, a subset of pUCM cells were found to 
morphologically resemble neurons and  to express pig-specific neuronal markers  
[33].  Here, the safety of pUCM cells for transplantation is evaluated by testing 
their potential to proliferate and the ability of pUCM cells to express tyrosine 
hydroxylase (TH) following transplantation into the brain of rats with a previous 
catecholaminergic (6-OHDA) lesion, a rodent model of PD.  
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Materials and Methods 
Cell culture and counting:  Pig UCM cells were cultured and maintained as 
described previously [19;33]  Manipulation of pUCM cells to express enhanced 
green fluorescent protein (eGFP) has been described previously [33].  Briefly, 
pUCM cells that were cultured in vitro 60 passages were transfected to express 
eGFP.  After several selection passages, the eGFP expressing pUCM cells were 
lifted by a trypsin solution. The cells were counted by a hemocytometer and were 
adjusted to a final concentration of approximately 150 cells per microliter.  The 
number of cells in one microliter was verified by spreading a 1 microliter drop on 
a plastic petri dish and manually counting the cells at 10x in bright field of a light 
microscope.  The cell concentration was confirmed before and after the injection 
to insure that approximately 150 cells were delivered. 
 
Transplantation procedure:  A guide cannula was implanted in the brain of 
anesthetized male Lewis rats (Harlan) via stereotaxic surgery into the right 
striatum (Bregma +0.5, Lateral 3.4, Ventral 5.0 mm from the surface of the 
brain)[25].  The cannula was attached to the skull with screws and dental acrylic.  
At least three days later, anesthetized animals received a single injection of 10 µl 
of 7mg/ml 6-hydroxydopamine (6-OHDA, Sigma) over 5 min.  At least one week 
after 6-OHDA injection, approximately 150 eGFP-pUCM cells in 1 µl of the sterile 
media were injected over 5 min.  Rat which received guide cannula, but did not 
receive a transplant or 6-OHDA, served as control. At 2, 4, 6 and 8 weeks post-
transplantation, two rats were randomly selected, anesthetized and sacrificed by 
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transcardial perfusion with heparinized isotonic saline rinse followed by 10% 
buffered neutral formalin. The brains were removed, postfixed, and cryoprotected 
in 20% sucrose overnight. Frozen sections of the brains were cut coronally at 40 
µm and the sections were collected into three sets of adjacent sections, each set 
consisting of every third serial section.   
 
Tissue processing and Immunocytochemical processing (IC):  
Immunocytochemical (IC) detection of a single antigen was performed on one set 
of sections as previously described [33] and the adjacent sets of sections were 
held in reserve in a cryoprotectant solution [32].  The free-floating tissue sections 
were stained with primary antibodies for GFP (rabbit host, 1:1000, Santa Cruz 
Biotechnology, Inc), TH (rabbit host, 1:2000, East Acres Biologicals), CD-4 
(mouse host, 1:500, Serotec), CD-8 (mouse host,1:500, Serotec), CD-11b 
(mouse host, 1:250, serotec), CD-161(mouse host, 1:250, Serotec) .  The 
antigens were visualized either with diaminobenzidine (DAB) and hydrogen 
peroxide using a commercially available ABC kit (Vectastain) or with 
immunofluorescence.  For immunofluorescence localization, 7-amino-4-
methylcoumarine-3-acetic acid (AMCA)- Avidin D (Vector Laboratories) was used 
with the biotinylated secondary antibody.  The IC-stained sections were mounted 
on subbed microscope slides, air-dried, and rinsed with distilled water.  To detect 
the immunofluorescence and eGFP staining, the sections were observed using 
epifluorescence illumination with the appropriate filter combinations on a Leica 
DMRD microscope after clearing and coverslipping with glycerol containing N-
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propyl gallate (3 parts 2% N-propyl gallate in 0.1M Tris buffer, pH 9.0 and 7 parts 
glycerol).  IC-stained cells were considered positive if: 1) the signal in the 
cytoplasm is above background and 2) if the signal was absent in tissues in 
which the primary antibody had been omitted.  To be considered double-labeled, 
the morphology and location of the cells must appear identical in both brightfield 
(DAB) and fluorescence (eGFP) for immunoperoxidase detected cells, or in both 
filter combinations for immunofluorescence (UV filter set for AMCA versus FITC 
filter set for eGFP). 
 
Cell size and number: To measure cell size and number, one set of sections 
were stained with anti-GFP antibody and localized with DAB.  A design-based 
unbaised stereological method is used for counting the cells.  Individual cells 
were identified in brightfield illumination and measured using an 
morphometry/image analysis system (Bioquant Nova Prime, R&M Biometrics).  
Graft cells that were identified in both brightfield (IC for GFP) and 
epifluorescence (GFP fluorescence) were measured.  With the experimenter-
blind to survival group, the area of at least 75 cells (cells which did not overlap 
with any other graft cell and had an obvious nucleus) was measured (this area 
represents cell size and the term "cell size" is used for cell area  throughout the 
manuscript) and the cell size distribution was analyzed for outliers and normality 
(StatView 5.0) and a frequency histogram was generated for each individual 
animal. To estimate the number of transplanted cells, the morphometry/image 
analysis software was used to measure the area occupied by graft cells in each 
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section (the area occupied by the graft cells in a particular section is assumed to 
be the volume of the graft in that section).  After measuring the graft cell area in 
all sections containing GFP IC-positive cells, the total area of the graft was 
represented as the sum of the area in each section.  No correction factors were 
applied. The total area of the graft was divided by the average cell size to yield 
an estimate of the number of graft cells detected in each set of sections.  
Because there are 3 sets of brain sections for each animal, the estimate of the 
total number of graft cells in the respective animal was three times the total 
number of graft cells in one set of sections. 
 
Assessment of TH-positive cells: A second set of brain sections was IC-stained 
for tyrosine hydroxylase (TH) and the TH antibodies were localized using AMCA.  
The TH-positive graft cells appeared in both the FITC filter set (eGFP) and the 
UV filter set (AMCA).  Again, with the experimenter-blind, an estimate of the 
percentage of graft cells that stained for TH was made by evaluating a minimum 
of ten fields per animal (fields were selected for counting based upon the 
distribution of cells in the field, e.g., fields were selected that did not have clumps 
of graft cells).  In each field, the number of eGFP cells (FITC) and the eGFP-TH 
positive cells (AMCA and FITC) were counted.  The percentage of TH-positive 
graft cells was calculated and averaged  to yield an estimate of the percentage of 
TH-positive graft cells in each animal. After the analysis was completed, the 
individual animals were assigned to the appropriate survival groups. To estimate 
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the total number of TH cells, the percentage of TH graft cells was multiplied by 
the graft cell number for each animal. 
 
Assessment of Host immune response: The frozen brain sections were IC-
stained using primary anti-rat CD4, CD8, CD11b or CD161 antibodies.  These 
primary antibodies were localized using biotinylated secondary antibodies and 
Avidin-AMCA. 
 
Statistical analysis: All tissue manipulations were conducted in large batches to 
avoid batch to batch differences in tissue IC-staining.  Tissue processing and 
data collection were conducted in an experimenter-blind fashion.  After 
measurements and counting, the survival group status was decoded prior to 
statistical analysis.  The histogram of the cell size was inspected for outliers 
(visual inspection of the distribution compared to a normal one).  If no outliers 
were observed, then the Kolmogorov-Smirnov (K-S) test was used to compare 
the distribution of measured cells size to an idealized normal distribution 
(Statview 5.0).  When outliers were observed, the Mann-Whitney U test was used 
to compare the distributions.  In all cases, no outliers were observed, thus the K-
S test was used here.  The K-S test revealed that all distributions were normal.  
Thus, ANOVA was used to test interactions between the independent variable 
(survival period after grafting) and the dependent variables (cell size, graft cell 
number, percentage of TH graft cells and number of TH graft cells).  Significance 
for ANOVA was set at p<0.05 (two tailed).  Following significant ANOVA, post 
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hoc analysis using Scheffe's F test was used to examine planned comparisons.  
Significance for post hoc testing was set at p < 0.05 (two tailed).   The mean plus 
or minus one standard error are presented on graphs.  
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Results 
Cannula placement   
In one of the eight animals, the guide cannula was misplaced.  This animal was 
excluded from further analysis (six week survival).  Because the six week survival 
period had only one animal with a good cannula placement, no data from that 
survival period is included.  Thus, the results presented are from the 2, 4 and 8 
week survival periods averaged from two animals at each survival period.  
 
Behavioral and histological findings   
None of the animals showed any behavioral abnormalities following the 
implantation of cannula.  Following 6-OHDA lesion, the animals demonstrated 
rotation (spontaneous) towards the damaged hemisphere during periods of 
excitement.  Rotational behavior was not quantified.  Following 6-OHDA lesion, 
the animals did not show other behavioral signs or changes in their health status.  
After the transplantation with eGFP-pUCM cells, the animals acted normally and 
appeared in robust health throughout the 2-8 week survival period (there was no 
indication of sickness behavior, weight-loss, etc).  Midbrain sections, when 
stained for TH, revealed destruction of most of the TH-positive dopaminergic 
cells in substantia nigra of the ipsilateral side of the 6-OHDA lesion, but not on 
the contralateral side (Fig. 2.1).    
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Figure 2.1: Histological findings in substantia nigra (SN) of the lesioned rats. A 
unilateral 6-OHDA lesion is created by injecting 6-OHDA in to the right striatum of 
all the rats under study. The mid brain sections were stained for TH to evaluate 
the effect of the lesion. Most of the TH-positive dopaminergic neurons in the 
ipsilateral (right) SN are destroyed (A; magnified view in B), but not in the 
contralateral (left) SN (A; magnified view in C). 
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Histological findings within the graft 
There was no evidence of tumor, teratoma or scar formation in the transplant 
recipients.  Withdrawal of host tissue was noted around the cannula implantation 
site in both control and grafted animals.  The pUCM-eGFP cells were identified 
by their endogenous candy apple green fluorescence (FITC filter cube, see Fig. 
2.2A).  To control for the possibility of auto-fluorescence by host cells, the 
sections were IC-stained using an antibody to GFP and visualized with AMCA.  
These results are shown in Fig 2.2B.  Virtually all the graft cells exhibiting GFP 
fluorescence were localized with AMCA. When the primary antibody is omitted, 
the graft cells were not observed using the UV filter set (Figs. 2.2C & D).  
 
The graft cells were localized by IC staining for GFP followed by DAB 
visualization.  Two weeks after transplantation, the graft cells were found along 
the sides and at the tip of the guide cannula tract.  Most of the graft cells were 
clustered.  Occasionally, individual cells were observed; most individual graft 
cells appeared small and spherical with a granular cytoplasm (Fig. 2.3A).  Four 
weeks after transplantation, the graft cells were found farther from the guide 
cannula tract in the surrounding host brain tissue.  At this time, more of the graft 
cells were dispersed and a greater percentage of the graft cells were elongated 
or bipolar in appearance.  Some of the graft cells had short, primary processes 
attached to the cell body (Fig. 2.3B).  Eight weeks after transplantation, the GFP 
staining in the graft cells was less intense and the graft cells appear larger and 
morphologically more complex when compared to the graft cells recovered 2  
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Figure 2.2: Appearance of pig UCM cells after transplantation into rat brain.  Pig 
UCM cells that were engineered to express eGFP were transplanted into the 
brains of rats that had a previous unilateral 6-OHDA lesion. The pUCM graft cells 
were recovered after 2, 4 and 8 weeks post-transplantation.  A. The eGFP-pUCM 
graft cells were identified by the epifluorescence (FITC filter set).   B. The brain 
sections were immunostained with anti-GFP serum and visualized using AMCA.  
The co-localization of AMCA with eGFP confirms the recovery of the graft cells. 
Virtually all of the graft cells show positive reaction with AMCA.  C, D. Control 
staining performed without the primary antibody for GFP shows no reaction for 
AMCA. 
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weeks post-transplantation (Fig. 2.3C).  No further migration was noticed from 4 
weeks to 8 weeks post-transplantation. Short processes were observed on a 
subset of the population of pUCM cells 4, 6 and 8 weeks after transplantation 
(see Fig. 2.4).  
 
Cell size 
Graft cells were identified by IC staining for GFP (visualized with DAB) and 
epifluorescence of GFP (FITC filter set).  From 75-110 cells per animal were 
measured and a frequency histogram of the cell size was created.  No outliers 
were observed.  All distributions were normal (K-S normality test) and unimodal. 
Next, the size distributions between animals at a given survival period were 
compared; there was no significant difference between cell size distributions at 
each survival period; those data were blocked for subsequent analysis by 
survival period (data not shown). At 2 weeks post-transplantation, the average 
size of the graft cells was 140.0 ± 3.7 sq. microns.  At 4 weeks post-
transplantation, the average size of the graft cells was 160.2 ± 12.1sq. microns.  
At 8 weeks post-transplantation, the average size of the graft cells was 171.9 ± 
2.3 sq. microns.  Thus, the graft cells at 8 weeks after transplantation were 22% 
larger than those at 2 weeks; this represents a significant increase in cell size 
(see Figure 2.5).      
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Figure 2.3: Pig UCM graft cells after 2, 4 
and 8 weeks post-transplantation.  The 
frozen brain sections of all the rats were 
immunostained with GFP antibody and 
localized with DAB.  A. After 2 weeks 
post-transplantation, the pUCM cells can 
be recovered and they appear round (black 
arrow), granular, tend to form clumps 
(white arrow) and are located just next to 
the cannula tract.  B. After 4 weeks post-
transplantation, the pUCM cells can be 
recovered. Some of the cells appear 
elongated (black arrow) and some appear 
to be extending small processes (white 
arrow). The graft cells are more scattered 
into the brain tissue around the cannula 
tract. C. After 8 weeks post-
transplantation, the pUCM cells can be 
recovered and appear to be bigger in size 
(black arrow) than after 2 and 4 weeks. A 
more diffused staining is noticed in the 
brain tissue around the cannula tract. 
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Figure 2.4: Pig UCM cells extend processes.  A subset of pUCM graft cells 
extend processes (black arrow) into the host's brain.  This may indicate that the 
graft cells respond to the local cues and differentiate into a neural phenotype. 
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Number of graft cells 
To estimate the proliferation of the graft cells in each individual, the total GFP-IC 
positive area in one set of sections (set A) was divided by the average cell size 
for that individual.  The estimated number of graft cells at each survival period is 
shown in figure 2.4.  At 2 weeks after transplantation, the estimated number of 
graft cells was 1825 ± 163 (yields a total of about 5475 graft cells per animal).  At 
4 weeks after transplantation, the estimated number of graft cells was 5758 ± 
400 (yields a total of 17274 graft cells per animal).  At 8 weeks after 
transplantation, the number of graft cells was estimated to be 6904 ± 1000 
(yields an estimated total of 20712 graft cells per animal).  The number of graft 
cells increases significantly from 2 to 4 weeks and 2 to 8 weeks (see Figure 2.5).  
This indicates that there is roughly a 5-6 fold expansion 2 weeks after 
transplantation and a 7-8 fold expansion of the original 150 graft cells by 8 weeks 
after transplantation. 
 
TH-positive graft cells 
The sections in set B were IC-stained using anti-TH antibody and visualized with 
AMCA. The graft cells that co-localized with green fluorescence for GFP (FITC 
filter set) and blue fluorescence for AMCA (UV filter set) are considered to be TH-
positive graft cells (Fig. 2.6A & B).  When the TH primary antibody was omitted, 
no positive staining for TH was observed (Figs. 2.6C & D).  The percentage of 
TH-positive graft cells is shown in figure 2.6. Two weeks post-transplantation, 1.0 
± 0.6 % of the graft cells were positive for TH.  Four weeks post-transplantation,  
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3.4 ± 0.6 % of the total graft cells were positive for TH.  Eight weeks post-
transplantation, 6.0 ± 0.3 % of the total graft cells were positive for TH.  Thus, 
there was a significant increase in the percentage of TH-positive graft cells at the 
8 week survival period compared with the 2 week survival period.  The estimate 
of total number of TH-positive graft cells at each survival period is shown in figure 
2.7. The total number of graft cells previously calculated was multiplied by the 
percentage of TH-positive graft cells.  It was estimated that a total of 54 TH-
positive graft cells were found in the two week survival animals, 587 TH-positive 
graft cells in the four week survival animals, and approximately 1242 TH-positive 
graft cells in the 8 week survival animals (see Figure 2.7).  Thus, there was a 
significant increase in the number of TH-positive graft cells at the 8 week survival 
period compared with the 2 week survival period. 
 
Host immune response 
There was no gross or significant histological evidence of immune rejection in the 
brain of the animals 2-8 weeks following transplantation, e.g., there was no 
vacuolization, perivascular cuffing, or cellular infiltrate. In addition, the frozen 
brain sections were IC-stained using anti-rat CD4, CD8, CD11b and CD161 
antibodies, and visualized with AMCA. IC-staining for anti-rat CD4 showed 
negligible staining; in contrast, the control animal, which received a cannula only, 
had variable and conspicuous staining for anti-CD4 antibody (see Figure 2.8).  
Similar results were observed when the sections were IC-stained using primary 
antibodies directed at CD8, CD11b, and CD161 (data not shown).   
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Figure 2.5: Pig UCM cell size and cell number.  150 pUCM cells were 
transplanted into rats with previous 6-OHDA lesions.  The cell size and number 
of grafted cells was evaluated at 2, 4 and 8 weeks post-transplantation. A. Cell 
size measured in 75-110 graft cells.  The distribution of size was tested and 
found to be normal with a single mean (data not shown).  The cell size is 
calculated for each animal and cell size at each survival period was calculated.  
B. The number of pig UCM cells was estimated in each animal.  The graft cells 
undergo about a five fold expansion in the first two weeks and increase to a 
maximum of about a seven fold expansion by the eighth week.  N=2 at 2, 4 and 8 
weeks. * P<0.05 
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Figure 2.6: Pig UCM cells stain for TH.  Approximately 150 pig UCM cells 
expressing eGFP are transplanted into rats with a previous unilateral 6-OHDA 
striatal lesion. The pUCM graft cells were recovered after 2, 4 and 8 weeks post-
transplantation. A. The pUCM graft cells can be identified by the green 
fluorescence of the GFP. B. The frozen brain sections were IC-stained using anti-
TH serum and visualized by AMCA. The co-localization of AMCA with eGFP 
confirms the TH-positive graft cells (white arrows).  TH-negative graft cells are 
indicated by white asterisks.  C, D. Control staining performed without the 
primary antibody for TH shows no reaction for AMCA (white arrowheads). 
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Discussion 
Here, approximately 150 pig UCM cells were transplanted into the brains of 
previously 6-OHDA lesioned rats and characteristics of the graft cells were 
determined over a 2-8 week survival period.  Specifically, the size and 
morphology of the graft cells, the total number of graft cells, and the percentage 
and number of pig UCM cells that synthesize tyrosine hydroxylase (TH) was 
determined at 2, 4 and 8 weeks after transplantation.  Four observations were 
made.  First, pig UCM cells increased in size over the 2-8 week period and a 
subset of the grafted cells extended short processes into the parenchyma of the 
host's brain.  Second, pig UCM cells proliferated rapidly in the first four weeks 
after transplantation, but the proliferation rate appears to slow over the next four 
weeks after transplantation (weeks 4-8 after transplantation).  Third, the 
percentage and total number of pig UCM cells that stain for TH significantly 
increased over the 2-8 week survival period.  Fourth, there was no apparent 
evidence of a significant host immune response to the transplantation of pig UCM 
cells.  These results indicate that pig UCM cells proliferated after transplantation 
and that a subset of the grafted cells that synthesize TH increased over the 2-8 
week survival period.  Also, the pig UCM cells appear to engraft without 
stimulating a significant immune rejection response over the 2-8 week period. 
 
Pig UCM cells were detected by GFP fluorescence and IC staining for GFP.  No 
positive GFP-IC staining, nor GFP fluorescence was found in the control animal 
which had a cannula but no graft cells (data not shown).  The expression of a  
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Figure 2.7: Percentage and number of TH-positive graft cells.  About 150 pig 
UCM cells were transplanted into the striatum of rats with 6-OHDA lesion. The 
percentage and number of TH-positive graft cells are evaluated at 2, 4 and 8 
weeks post-transplantation. A. The percentage of TH stained graft cells was 
determined in at least ten fields per animal. The percentage of TH-positive graft 
cells increases over the time (1% at 2 weeks to about 6% at 8 weeks post-
transplantation). B. Based on the total number of graft cells and the percentage 
of TH stained graft cells, the number of TH-positive graft cells was calculated. 
The number of TH-positive graft cells increases from about 50 at 2 weeks to 
about 1200 cells at 8 weeks post-transplantation. * P<0.05 
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marker protein such as GFP over the 2-8 week survival period following 
transplantation supports the notion that pig UCM cells have not been scavenged 
by the immune system.  In previous work, lysed pig UCM cells were injected into 
the rat brain and no stained cells (neither host or graft cells) were detected at the 
injection site [33].  This indicates that either cellular debris or the leakage of GFP 
from dead or dying cells does not produce non-specific staining.  It was observed 
that GFP staining was less intense in animals with the longest survival times 
compared to those animals that survived two weeks.  The reason for the 
decrease in intensity is unknown.  Also, the grafted cells increased in average 
size over time; the reason for this is not understood.  
 
Here, 150 cells were transplanted because previous work has shown that the 
number of cells in a graft may influence graft survival or function.  For example, 
Ostenfeld et al. compared human neural precursor cells that were transplanted at 
200,000 cells (low density), or high-density grafts (1-2 million cells)[21].  They 
reported that low-density grafts had significantly fewer host immune cells 
compared to animals with high-density grafts.  They found that the low-density 
grafts have a higher proliferation rate 2-6 weeks after transplantation, and 
compared to the high-density grafts, the low-density grafts had more fiber 
outgrowth [21].  Bjorklund et al. transplanted 1000-2000 undifferentiated ES cells 
and found proliferation in the rat brain [3].  These authors noted that when a high 
concentration of ES cells were transplanted, there was a greater likelihood of 
teratoma formation [3].  They speculated that when cells are transplanted at low  
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Figure 2.8 Host immune cell infiltration into the injection site.  The frozen brain 
sections were IC-stained using anti-CD4 antibody and visualized by AMCA. A. 
No significant evidence of immune cell infiltration; few CD4-positive cells are 
found in the site of pig UCM cell transplants.  B. Pig UCM graft cells expressing 
GFP. C. A variable and conspicuous staining for anti-CD4 antibody was found 
around the cannula tract of control animal which had no graft cells.  Similar 
staining was obtained for CD8, CD11b and CD161 (data not shown). 
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concentration, the cell-to-cell contact will be less and the cells will be influenced 
by the local host signals leading to increased differentiation to neural cells.  In 
their work, 2000-2500 TH-positive cells were recovered 14 – 16 weeks after 
transplantation [3]. Thus, similar to the present findings, previous work 
demonstrates that stem cells can proliferate and differentiate into TH-positive 
cells following xenografting. In contrast to the present findings, the work reviewed 
above was conducted in animals that were receiving immune suppression 
therapy. 
 
We have shown that UCM cells are a type of primitive stem cell that can 
differentiate into neural cells in vitro [19] and pig UCM cells engraft following 
central or peripheral injection of 10,000 cells into rats without requiring immune 
suppression [33].  Pig UCM cells, after transplantation into rat brain, were shown 
to stain for pig-specific neurofilament and other neural markers [33].  In those 
experiments, the number of cells in the graft could not be determined because of 
the high-density grafts and wide distribution of the cells in the host brain tissue.  
The present work follows the previous work and demonstrates that UCM cells 
apparently proliferate during the first 4 weeks following transplantation, but this 
growth rate tapers apparently during the next 4 weeks. The decrease in the rate 
of proliferation after 4 weeks allows us to speculate that the cells might stop 
proliferating after a while, and we intend to address this speculation in our future 
work with longer survival period.  Further, over the 2-8 week survival period, the 
percentage and number of TH-positive graft cells increases. In future work, the 
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number of graft cells undergoing apoptosis and division will be assessed using 
TUNEL staining and Ki67 staining over time. 
 
Tissue transplantation has associated complications such as graft versus host 
disease (GVHD) and immune rejection of the graft by the host.  The rat is a 
model system to study rejection of grafted tissue.  For example, transplantation 
of fetal pig brain tissue into rat brain results in a significant host immune 
response and the grafted material is cleared from the rat brain in 2-6 week period 
after transplantation [4;9;10;13-15;34].  The clearance of the grafted tissue is 
correlated with an infiltration of host immune cells.  In contrast, transplantation of 
tissues that are generated from the same species, an allograft, has less tissue 
rejection problems than a xenograft [10].  In the rat, treatment with immune 
suppressive drugs is not successful at blocking the immune response to a 
xenograft [8], but immune suppression does increase the survival rate of the graft 
significantly [4;23].  Rejection of the grafts remains a hurdle to therapeutic neural 
xenografting [4].  
 
In contrast to the rejection problems observed during xenotransplantation of 
tissue, here, approximately 20,000 GFP-positive graft cells were recovered 8 
weeks after transplantation with no significant host immune response.  There are 
several possible explanations for this observation.  First, pig UCM cells may have 
immunosuppressive effects like another type of stem cell [16].  Second, the low 
number of graft cells used here may not provide a sufficient stimulus for rejection.  
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Indeed, previous work has indicated that the number of cells in the transplant can 
affect differentiation to neurons and survival [3;20].  Third, in humans, cells 
located at the feto-maternal interface contain HLA-G which has been suggested 
to play a role in dampening the mother's inflammatory and immune response 
against the fetus [6;17;24;26-29].  In preliminary work, human UCM cells stained 
for HLA-G [31].  Hypothetically, pig UCM cells may synthesize an analogue of 
HLA-G which may dampen the rat's immune response. Further work is needed to 
understand how UCM cells avoid immune surveillance.  
 
Therapeutic potential of stem cells for neurodegenerative diseases has been 
demonstrated in rodent models [11]. One hypothesis for their therapeutic role is 
that stem cells are attracted to the neurodegenerative environment, where they 
replace dead cells [2] or rescue sick or dysfunctional cells [22]. Here, rats with a 
previous unilateral 6-OHDA lesion received 150 pig UCM cells.  From these 150 
transplanted cells,  the number of TH-positive pig UCM cells increased from 
about 50 at 2 weeks post-transplantation to more than 1200 cells after 8 week 
survival.  Exceeding 1000 TH-positive cells may be significant because it was 
previously estimated that 1000 dopaminergic cells are needed for behavioral 
recovery in a rat model of Parkinson's disease [30].  This finding, together with 
the lack of significant host immune response to the xenograft, would suggest that 
transplantation of pUCM cells may provide a therapeutic approach for the 
treatment of neurodegenerative diseases such as Parkinson’s disease. 
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Abstract 
 
The umbilical cord contains an inexhaustible, non-controversial source of stem cells for 
therapy.  In the United States, stem cells found in the umbilical cord are routinely placed 
into biohazardous waste after birth.  Here, stem cells derived from human umbilical cord 
Wharton=s Jelly, called umbilical cord matrix stem (UCMS) cells, are characterized.  
UCMS cells have several properties that make them of interest as a source of cells for 
therapeutic use.  For example, they: 1) are isolated in large number; 2) are negative for 
CD34 and CD45, 3) grow robustly and can be frozen/ thawed, 4) can be clonally 
expanded, and 5) can easily be engineered to express exogenous proteins.  UCMS 
cells have genetic and surface markers of mesenchymal stem cells (positive for CD10, 
CD13, CD29, CD44, CD90, and negative for CD14, CD33, CD56, CD31, CD34, CD45 
and HLA-DR), and appear to be stable in terms of their surface marker expression in 
early passage (passages 4-8).   Unlike traditional mesenchymal stem cells derived from 
adult bone marrow stromal cells, small populations of UCMS cells express endoglin 
(SH2, CD105) and CD49e.   UCMS cells express growth factors and angiogenic factors 
suggesting that they may be used to treat neurodegenerative disease.  To test the 
therapeutic value of UCMS cells, undifferentiated human UCMS cells were transplanted 
into the brains of hemiparkinsonian rats that were not immune suppressed. UCMS cells 
ameliorated the apomorphine-induced rotations in the pilot test.  UCMS cells 
transplanted into normal rats did not produce brain tumors, rotatory behavior or a frank 
host immune rejection response.  In summary, the umbilical cord matrix appears to be a 
rich, non-controversial and inexhaustible source of primitive mesenchymal stem cells.  
 
 75 
Key words: Wharton's jelly, flow cytometry, regenerative medicine, in vitro expansion, 
non-controversial source of stem cells 
 76 
Introduction 
Stem cells derived from embryos (embryonic stem cells, ESCs) or fetal tissues have the 
potential for therapeutic use.   Both ESCs and fetus-derived stem cells have significant 
problems which impede their adaptation into the clinic, not the least of which are the 
moral/ethical issues surrounding their derivation (1-7).   
 
With regard to moral/ethical issues, postnatal stem cells offer fewer concerns.  Dogma 
has it that, in contrast to fetus-derived stem cells or ESCs, postnatally-derived stem 
cells have less broad developmental potential.  This dogma has no real teeth: several 
labs have shown that postnatal stem cells have wide potential, e.g., (8-11). 
 
At least two types of stem cells have be found in umbilical cord/placental tissues: blood-
forming stem cells (hematopoietic stem cells, HSCs) and mesenchymal stem cells 
(MSCs).  Umbilical cord blood (UCB) is a source of a population of pluripotent, 
mesenchymal-like stem cells (8) and hematopoietic stem cells (HSC) for 
transplantation.  UCB is rapidly gaining attention for its therapeutic value for several 
reasons.  First, UCB has more primitive HSC per volume than bone marrow (12).  
Second, there is a lower incidence of rejection after UCB transplantation (13-15). Third, 
unlike bone marrow transplants, UCB transplantation does not require perfect antigen 
matching (13).  Fourth, UCB transplantation has been useful for the treatment of inborn 
errors in metabolism (16).  Finally, the methods for collecting, storing and freezing 
human blood were developed in the 1940s, so no new technology is needed to save the 
mononuclear cells from UCB.  This has led to the establishment of cord blood banks 
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and the increased use UCB for transplantation (17,18).  Interestingly, non-hematopoietic 
stem cells derived from umbilical cord blood have been shown to produce cytokines that 
may facilitate engraftment and ex vivo expansion and are more effective than bone 
marrow derived mesenchymal stem cells for in vitro expansion of HSCs from CB (19). 
 
The umbilical cord vessels and surrounding mesenchyme (including the connective 
tissue matrix that becomes Wharton=s jelly) are derived from extraembyronic mesoderm 
and/or embryonic mesoderm.  Thus, these tissues, as well as primordial germ cells, 
differentiate from the proximal epiblast around the time of primitive streak formation 
(20). There are several reports of mesenchymal stem cells (MSCs) or somatic stem 
cells with pluripotent differentiation potential from various sites in the umbilical cord 
(8,21-25).  Thus, these tissues are rich sources of stem cells that may be useful for a 
variety of therapeutic purposes.  We speculate that the umbilical cord matrix material 
derives from primitive mesenchyme that is in a transition state to the mesenchyme 
found in the bone marrow niche of adult animals.  Here, we investigate this hypothesis 
by characterizing the human umbilical cord matrix stem cells and comparing them with 
stem cells derived from other sources.  
 
As mentioned above, umbilical cord tissues contain pluripotent stem cells.  We 
speculated that these stem cells may be useful for treating neurodegenerative disease, 
such as Parkinson=s disease.  Previous work has indicated that cells derived from 
embryonic or fetal sources may be useful when transplanted into PD rodents (26-30). In 
our previous work, we found that pig umbilical cord matrix stem cells engrafted and 
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expanded significantly without forming teratomas, when transplanted into rats with 6-
hydroxydopamine lesions of the striatal-nigral tract (31,32).  Here, to test the  value of 
human umbilical cord matrix stem cells, we expanded upon our previous work by testing 
the behavioral effects of human umbilical cord matrix cells in the PD rat model. 
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Material and Methods 
 
Human subjects: 
The work was conducted following approval of the Kansas State University human 
subjects board (IRB approval # 3515).   
 
Generation and expansion of UCMS cells: 
The collection and expansion of UCMS cells was described previously (24).  Briefly, 
human umbilical cords from both sexes were collected from full-term births (two sets of 
fraternal twins) with informed consent of the mother after either C-section (11 of 14) or 
normal vaginal delivery and aseptically stored at 4oC in sterile saline until processing.  
To isolate UCMS cells, the cord was rinsed several times with sterile saline and cut into 
2-4 cm lengths.  The interval between collection and isolation of UCMS cells ranged up 
to 48 hr.  To isolate UCMS cells, the cord blood was drained and clots flushed from the 
vessels.  Next, the vessels were stripped manually from cord segments, the wall of the 
cord was opened and the tissue immersed in an enzyme cocktail (such as 
Hyaluronidase, trypsin and Collagenase) for 45-60 min at 37oC.  This tissue was then 
crushed with forceps to release individual UCMS cells and large pieces of tissue were 
removed.  The cells were pelleted by low speed centrifugation (250g for 5 min), 
suspended in fresh media and plated onto hyaluronic acid (HA)-coated plastic plates.  
Pilot work indicated that HA-coated plates optimized the attachment of UCMS cells. 
 
 80 
Several different media support the growth of the adherent UCMS cells: a low serum, 
Adefined media@ (56%  low glucose DMEM (Invitrogen), 37% MCBD 201 (Sigma), 2% 
fetal bovine serum (FBS, Mediatech, MTT 35-010-CV), 1x insulin-transferrin-selinium-A 
(ITS, Invitrogen), 1x ALBUMax1  (Invitrogen), 1x Pen /Strep (Invitrogen), 1x 
Amphotericin-B (ICN-1672348), 10 nM dexamethasone (Sigma), 50 µM ascorbic acid 2-
phosphate (Sigma), 1 ng/ml epidermal growth factor (EGF, R&D systems), 10 ng/ml 
platelet derived growth factor-BB (PDGF-BB, R&D systems)) or the same media without 
ascorbic acid and dexamethasone.  This media was used for all the experiments 
described here.  Cells were incubated at 37oC in an incubator with 5% CO2 at saturating 
humidity.  When cells reached 70-80% confluency or when numerous colonies were 
observed, the cells were detached with 0.25% trypsin-EDTA (Invitrogen), the trypsin 
was inactivated with fresh media, centrifuged for 250g for 5 min, and  and replated on 
HA-coated plates 1:3.  UCMS cells could be stored frozen at -135oC in a freezing media 
containing 1:1 defined media: 80% FBS, 20% DMSO, or in 93% FBS, 7% DMSO, or  
93% FBS and 7% glycerol, alone, after removal of the media. To demonstrate that 
human UCMS cells have the capacity for clonal expansion, clonal lines were 
established by the removal of a single cell to an individual well of a 24 well plate.  The 
addition of a single cell per well was confirmed visually for each well using phase 
contrast microscopy.  To determine whether human UCMS cells were karyotypically 
stable in culture, human UCMS cells from various passages (2-13) were selected for 
karyotypic analysis as described (33,34). 
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Total RNA 
Total RNA was collected from human UCMS cells (various passages from 2-8). Human 
bone marrow mesenchymal stem cells (MSCs) were purchased from Cambrex and 
grown using the manufacturer=s protocol.  Total RNA from MSCs was collected from 
passage 5.  Undifferentiated human ESCs were obtained from WyCell (H1) using the 
supplied protocol.  RNA was isolated either with TRIZOL LS using manufacturer=s 
protocol or by Qiagen Rneasy kit using manufacturer=s protocol.  The RNA was treated 
with Dnase and stored at -80oC.  Total RNA from USSC and from nestin-positive islet 
precursors (NIPs) was supplied from ViaCell (Andrei Kritsov and Elizabeth Abraham, 
respectively).  
Flow cytometric analysis of UCMS cells 
The cells were analyzed by flow cytometry in two independent labs (KSU and ViaCell 
SRC).  To stain the UCMS cells, the cells were lifted with trypsin and the trypsin was 
inactivated with fresh media.  Approximately 106 cells were pelleted and resuspended in 
PBS and fixed with 4% buffered paraformaldehyde for 5 min at room temperature.  To 
stain, the non-specific binding was blocked with PBS with 2% normal serum for 5 min, 
and then the cells were incubated with primary antibody for 45 min at room temperature.  
The cells were stained with a fluorescent secondary antibody for 30 min.  Control cells 
were prepared by incubation with the secondary antibody alone.  In each case, the cells 
were gently pelleted and washed with PBS rinses between each incubation step.  For 
cytoplasmic antigens, the cells were permeablized by 100% cold methanol for 5 min. 
Antibodies used are shown in supplemental table 3.1. 
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RT-PCR 
The cDNA was synthesized using 0.2-1 µg total RNA in the presence of Superscript II 
and oligo(dT)12B18 (both from Invitrogen).  The DNA sample was treated with Rnase H 
and stored frozen until use.  PCR was performed in a 20-µL reaction solution containing 
2 µL 10x PCR buffer, 150 µmol MgCl2, 10 µmol dNTP, 20 pmol primer, 1 µL 10 _ diluted 
cDNA and 1 U RedTag DNA polymerase (Sigma). The PCR conditions were as follows: 
5 min at 94oC followed by 35 cycles of 94oC for 30 s, 55oC for 30 s and 72oC for 60 s, 
and final extension for 10 min at 72oC.  Primer sequences are provided in supplemental 
table 3.2.  
 
Focused Gene array analysis. 
The non-radioactive GEArray cDNA expression array filters (HS-601.2; SuperArray Inc.) 
were used and hybridization procedures were as described by the manufacturer.  Total 
RNA was checked spectrophotometrically or by gel.  Biotin dUTP-labeled cDNA probes 
were specifically generated in the presence of a designed set of gene-specific primers 
using total RNA (4 µg per filter) and 200 U Moloney Murine Lukemia Virus (MMLV) 
reverse transcriptase (Promega, Madison, WI, USA). The array filters were hybridized 
with biotin-labeled probes at 60oC for 17 h. The filters were then washed twice with 2x 
saline sodium citrate buffer (SSC)/1% sodium dodecyl sulfate (SDS) and then twice with 
0.1x SSC/1% SDS at 60oC for 15 min each. Chemilumilescent detection steps were 
performed by subsequent incubation of the filters with alkaline phosphatase-conjugated 
streptavidin and CDP-Star substrate.  The microarray experiments were performed 
multiple times with new filters and with RNA isolated from different passages from the 
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same umbilical cord and from different umbilical cords. The Z transformed data from all 
samples are in supplemental table 3.3.  Here, the averaged z-transformed data from the 
fifty most highly expressed genes are presented (table 3.2) 
 
Testing therapeutic effect of UCMS cells in Parkinsonian rats. 
The hemi-parkinsonian rat model: 
Brain damage was induced by a single stereotaxic injection of 6-hydroxydopamine (6-
OHDA) as previously described (35).  Anesthetized female Sprague-Dawley rats 
received a 4.0 µl injection of 32 mM 6-OHDA HCl (Sigma) dissolved in 0.02% ascorbate 
at 1 µl/min into the left medial forebrain bundle (Bregma -2.8; lateral 2.0; ventral 8.4mm; 
incisor bar 3.9mm ventral to interaural axis) or an injection of  vehicle (sterile saline) four 
weeks prior to transplantation.  The lesioned animals showed spontaneous rotations 
upon recovery from lesion surgery.  Following surgery, rats were monitored for 
behavioral changes, weight loss and overall health.  Four weeks following lesion 
surgery the animals received the human UCMS cell transplant or sham transplant 
(sterile saline).  The efficacy of the 6-OHDA lesion was assessed by apomorphine-
induced rotations every two weeks following the lesion and also by characterizing the 
staining for TH in the ipsilateral and contralateral striatum and ventral midbrain after 
sacrifice (sees below).  
 
Behavioral Assessment 
To test, rats were placed in round, opaque testing chambers and allowed to acclimate 
for 5 minutes prior to receiving the apomorphine injection (0.1 mg/kg, sc).  The number 
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of rotation numberrotations and the direction was counted for a 30 minute period after 
giving apomorphine injection.  Four weeks following the lesion, rats that did not exhibit 
at least 200 rotations/30 minutes toward the contralateral side after apomorphine 
treatment were excluded from the experiment.  Recovery of function was evaluated over 
time (repeated measures) and pooled across groups to compare treatments. 
 
UCMS transplantation. 
At four weeks after brain lesion, animals were behaviorally tested and randomly 
assigned to transplantation or sham-transplantation groups.  Approximately 1000 
human UCMS cells in 1µl of the sterile PBS were injected over 5 min into the striatum 
(Bregma +0.5, Lateral +3.4, Ventral -5.0 mm from the surface of the brain).  All animals 
received UCMS cells from the same passage (passage 9) on the same day.  Before 
transplantation, the cells were lifted by a trypsin solution and were counted by a 
hemocytometer, and were adjusted to a final concentration of approximately 1000 cells 
per microliter.  The cell concentration was confirmed before and after the injection to 
insure that approximately 1000 cells were delivered.  Multiple control groups were used 
such as, 1. Lesioned rats with sham transplant (saline), 2. Non-lesioned rats with 
hUCMS cell transplant, 3. Non-lesioned rats with sham transplant (saline). At 6 and 12 
weeks post-transplant, 12 rats were randomly selected from the experimental groups, 
anesthetized and sacrificed by transcardial perfusion with heparinized isotonic saline 
rinse followed by 10% buffered neutral formalin. The brains were removed, postfixed, 
and cryoprotected in 20% sucrose overnight.  Frozen sections of the brains were cut 
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coronally at 40 _m and the sections were collected into six sets of adjacent sections, 
each set consisting of every sixth serial section. 
Tissue processing and Immunocytochemistry 
Immunocytochemical (IC) detection of a single antigen was performed on one set of 
sections as previously described (32) and the adjacent sets of sections were held in 
reserve in a cryoprotectant solution(36).  The free-floating tissue sections were stained 
with primary antibodies for anti-human nuclear antigen (mouse host, 1:30, Chemicon), 
TH (rabbit host, 1:2000, East Acres Biologicals), anti-rat CD-4 (mouse host, 1:500, 
Serotec), anti-rat CD-8 (mouse host, 1:500, Serotec), and anti-rat CD-11b (mouse host, 
1:250, Sserotec), anti-rat CD161 (mouse host, 1:250, Serotec).  The antigens were 
visualized either with diaminobenzidine (DAB) and hydrogen peroxide using a 
commercially available ABC kit (Vectastain) or with immunofluorescence.  For 
immunofluorescence localization, 7-amino-4-methylcoumarine-3-acetic acid (AMCA) - 
Avidin D (Vector Laboratories) was used with the biotinylated secondary antibody.  The 
IC-stained sections were mounted on subbed microscope slides, air-dried, and rinsed 
with distilled water.  Immunofluorescence in the sections was observed using 
epifluorescence illumination with the appropriate filter combinations on a Leica DMRD 
microscope after clearing and coverslipping with glycerol containing N-propyl gallate (3 
parts 2% N-propyl gallate in 0.1M Tris buffer, pH 9.0 and 7 parts glycerol).   
 
Counting TH-positive cells in SN and VTA 
The TH-positive DA neurons in substantia nigra (SN) and ventral tegmental area (VTA) 
were counted using a design-based unbiased stereological method and a 
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morphometry/image analysis system (Bioquant Nova Prime, R&M Biometrics).  One set 
of brain sections of all the experimental animals were stained with anti-TH antibody and 
visualized with DAB.  In each section the region of interest was outlined (SN and VTA), 
and the number of TH-positive cells per sq. mm. of that region were selected and semi-
automatically counted.  The SN and VTA TH-positive cells were counted, and the 
average number of TH-positive DA neurons per mm2 was calculated for each animal. 
 
Statistical analysis 
All tissue manipulations were conducted in large batches to avoid batch to batch 
variability in tissue IC-staining.  Data collection was conducted in experimenter-blind 
fashion.  Following data collection, the group status was decoded prior to statistical 
analysis.  In general, analysis of variance (ANOVA ) was used to evaluate group 
differences.  ANOVA was followed by post hoc testing using Scheffe=s test.  
Significance was set at p<0.05. Data is presented as mean _ standard error of the mean 
(SEM) throughout. 
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Results: 
Characterizing UCMS cells.   
Culture:  
Human UCMS cells were isolated from 15 of 17 cords.  We isolated 15-17x103 cells per 
cm of cord length (range: 10-50 x 103 cells per cm).  The primary isolates were 
heterogeneous with mesenchymal-like cells possessing short and long processes as 
well as small round cells with a high nuclear to cytoplasm ratio (see supplemental figure 
3.1).  Individual cells could be clonally expanded.  Through 10 passages, the 
populations are morphologically and immunophenotypically similar to the parent (data 
not shown).  Clonally derived lines of human UCMS cells were confirmed by visual 
inspection that a single UCMS cell was delivered per well of a 24 well plate.  The clonal 
capacity is estimated at a rate of 1-4 clonal populations derived per 48 attempts (data 
not shown).  The clonal lines were not analyzed further. Human UCMS cells from four 
isolates were GTG-banded and chromosomes evaluated.  None of the isolates were 
abnormal; the karyotype of the cells was stable through 13 passages (approximately 30 
population doublings) (supplemental figure 3.2).  
Flow cytometry and sorting of Hoechst dim cells: 
A relatively large percentage of UCMS cells exclude Hoechst dye (Hoechst-low, 
average of 23%, N=4, range 8-32%).   About 85% of the Hoechst-low stained are also 
CD44 positive (figure 3.1).  Interestingly, sorting dim Hoechst cells did not enrich for 
CD44 stained cells (data not shown).  To determine whether the Hoechst-low/CD44 
positive population could be enriched further and expanded, the Hoechst-low  
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Supplemental Figure 3.1: Morphology of HUCMS cells.   Most cells are mesenchymal in 
appearance, with a minor population of attached, small, round cells. 
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Supplemental Figure 3.2: Representative HUCMS karyotype.  Four HUCMS isolates 
were karyotyped (P10-P14), all were normal.  This karyotype was isolated from a term 
human umbilical cord and passaged 11 times.   
 
 
 
 
 90 
population was sorted using FACS.  The sorted Hoechst-low staining cells appeared 
morphologically distinct from the Hoechst-bright population, with a higher percentage of 
the cells being the small round cells (see figure 3.1, middle).  The enriched population of 
Hoechst-low cells was expanded through 5 passages and the percentage of Hoechst-
low and CD44-positive cells was again assessed.  At this time, the two populations 
looked morphologically similar and 23.5% of the cells were Hoechst-low sorted 
population and 20% in the Hoechst-bright population.  Presently, enrichment for 
Hoechst dim cells by flow sorting is not maintained after passage.  Previous work has 
indicated that Hoechst low staining is due to the presence of the ABCG2 receptor 
(37,38).  As shown in figure 3.1, bottom, human UCMS cells showed the characteristic 
surface staining for the ABCG2 receptor and CD44.  Verapamil (VP, 10 µM) was used 
as a non-specific blocker of the Hoechst dye exclusion channels.  VP treatment partially 
blocked Hoechst dye exclusion from 24% dye excluding cells without VP to 7% dye 
excluding cells with VP (data not shown). 
Flow cytometry: 
Human UCMS cells from passage 4 and passage 8 from two different cord samples 
were characterized by flow cytometry (see Table 3.1; representative histograms of this 
data can be found in supplemental figure 3.3).  UCMS cells stained positively for CD10 
(average of 58% in P4 and 64% in P8), CD13 (average of 58% in P4 and 79% in P8), 
CD29 (average of 89% P4, 83% P8), CD44 (average of 85% P4, 74% in P8), CD90 
(average of 70% in P4 and 41% in P8), HLA-1 (average 43% P4, 55% P8).  A smaller 
number of UCMS cells express CD49e (average of 5% P4 and 5% P8) and CD105  
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Figure 3.1: Flow cytometry and FACS of HUCMS cells.  TOP LEFT: HUCMS cells 
stained for Hoechst 33342 revealed a population showed low fluorescence (see box) 
that comprised about 20% of the cells.  When this population was sorted off and stained 
for CD44 expression, about 85% of the Hoechst-low cells express CD44. Hoechst-low 
(TOP RIGHT).  Middle panel: The two populations, Hoechst-dim and Hoechst-bright 
were expanded in vitro.  The morphology of the two populations is shown in the middle 
two panels: Hoechst low (LEFT) and Hoechst bright (RIGHT).  Following expansion and 
passage the two populations were again Hoechst and CD44 stained.  
Immunocytochemistry was used to verify ABCG2 (the transporter thought to be 
responsible for Heoscht dye efflux)(Bottom left) and CD44 (a mesenchymal cell marker 
that is the hyaluronate receptor)(Bottom right). 
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Table 3.1: Flow cytometry data 
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Supplemental Figure 3.3: Representative flow cytometry results.  Flow cytometry data 
for one cord sample (HUC 10) at passage 8.  The gray histogram is the cell staining 
following isotype control, the white (unfilled) histogram is the antibody-stained cells.  
The percentage of cells staining for each surface marker is provided in table 3.2. 
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(average of 7% in P4 and 9% in P8).  CD14, CD31, CD33, CD34, CD45, CD56, CD133, 
and HLA-DR were not detected (Table 3.1).   Note that the percentage of cells staining 
was fairly stable over four passages examined with no clear trends (Table 3.1).  
Neural potential of hUCMS Cells. 
A majority of undifferentiated UCMS cells stain for glial-cell line derived neurotrophic 
factor (GDNF, see Figure 3.2, top left).  Immunocytochemistry for GDNF showed the 
staining evenly distributed through the cytoplasm of the cells (see Figure 3.2, top right). 
Neural induction, using the methods described by Woodbury et al. (39), resulted in a 
decreased number of cells expressing the marker for early neural progenitors, e.g., 
nestin, and an increased number of cells expressing the marker for catecholaminergic 
cells, tyrosine hydroxylase, a mature neural marker (see figure 3.4, bottom). 
Gene array results for undifferentiated hUCMS cells. 
Human UCMS cells express many different genes, suggesting that they are 
promiscuous in the production of genes as has been described for other stem cells such 
as hematopoietic stem cells and embryonic stem cells (40,41).  The fifty genes that 
were most highly expressed by human UCMS cells are shown in table 3.2(note: the z-
transformed data for all array elements is provided in supplemental table 3.1). Of the top 
fifty genes, genes found expressed in undifferentiated embryonic stem cells (ESCs) that 
were also expressed in the UCMS were: LIF receptor pathway, ESG1, SOX2, and 
TERT.  Human UCMS cells express genes for proteins associated with morphogenesis: 
SHH, neuregulin1 and 4, Patched, SNA2, and WNT4. In addition, human UCMS cells 
express extracellular adhesion molecules: N-cadherin, V-cadherin, R-cadherin, integrin 
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Figure 3.2: A. Production of glial cell line-derived neurotrophic factor (GDNF) by 
HUCMS cells.  More than 80% of the cells are positive as revealed by flow cytometry 
(left).  The immunocytochemical staining confirmed the flow cytometry findings (right).  
B. Effect of differentiation of UCM cells on expression of nesting and tyrosine 
hydroxylase staining.  The expression of nestin, a marker of the primitive neural stem 
cells, decreases in the differentiated cells (10.03%) compared to undifferentiated cells 
(23.41%). The expression of tyrosine hydroxylase (TH), a marker of catecholaminergic 
neurons, increased in differentiated cells (63.23%) compared to the undifferentiated 
cells (20.1%). 
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beta 1, integrin alpha 5, VCAM 1, integrin alpha 2 (CD49b), integrin alpha V, integrin 
beta 5, integrin alpha 4, and integrin alpha 3.  Human UCMS cells express genes of 
proteins shown to have a neurotrophic effect: CNTF, VEGF, FGF20 and TRKC.  Human 
UCMS cells express markers of three germ layer derivatives: mesoderm: ACTG2, 
ACTA2, BMP1, PDGFB; ectoderm: keratin 8, SHH, endoderm: insulin.  In contrast to 
what was seen with gene array, neither flow cytometry (table 3.1) nor RT-PCR (data not 
shown) detected CD34.   
RT-PCR:  
The gene expression profile of UCMS cells and two other cell types, Nestin-positive Islet 
Precursor cells (NIP, a generous gift from Elizabeth Abraham, ViaCell, Cambridge MA) 
and bone marrow-derived mesenchymal cells (MSCs, Cambrex), and positive human 
control RNA (liver, placenta and muscle, BioChain, Hayward CA) was evaluated using 
RT-PCR to confirm or expand the gene array results.  As shown in figure 3.3(left), 
human UCMS cells express markers of the undifferentiated state, Oct4, FGFR4, LIFR, 
Glut-1, ABCG2, Nanog, and Rex-1 as detected by RT-PCR.  Human UCMS cells also 
express genes of proteins from all three germ layers and trophectoderm. 
Trophectoderm markers were Bex1/Rex3, Hand1, and HEB (figure 3.3, middle panel).   
Neurectoderm markers were nestin.  Mesoderm markers were CXCR4, vimentin, CD44, 
collagen X, and Flk-1 (figure 3.3center and right panel).  Endoderm markers were PDX1 
and islet-1. Figure 3.3, right panel shows the expression of UMCS cells compared with 
MSCs.  The two cell types were similar in the expression of OPN, ABCG2, CD44, LIFR, 
and collagen I, alpha1.  One notable difference was the UMCS cells expressed Flk-1. 
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Figure 3.3  RT-PCR data comparing human UCMS cells to various other cell types with 
regard to markers for pluripotent cells (left), trophectoderm or germ layers (middle), and 
some miscellaneous markers (right).  NIP: nestin positive islet percursors (ViaCell, Inc); 
Control RNA: placenta (top three rows), liver (rows 4-8), heart muscle (bottom row); 
MSCs: bone marrow mesenchymal stem cells (Cambrex), ESC: a mixed total RNA from 
several approved human embryonic stem cell lines (supplied by MSR).   
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Effect of UCMS cells in Parkinsonian rats. 
Behavioral assessment 
The PD model rats that received the human UCMS cell transplant showed a significant 
decrease in the number of rotations compared to the sham transplanted animals (see 
Figure 3.4).  Non-PD model animals with and without human UCMS cell-transplant did 
not rotate following apomorphine treatment (these data point overlay each other in 
Figure 3.4).  In retrospect, we concluded that the grafts were unlikely to be effective in 
all animals, so post hoc, the animals that responded to the transplant, e.g., decreased 
their rotations following transplant of hUCMS cells, were identified (indicated by boxed 
region on right of Figure 3.4).  The data from individual animals is shown in figure 3.4, 
right side.  This data shows that at six weeks post transplant 2 out of 4 animals 
responded (decreased rotations by about 60%).  At 12 weeks survival, 3 out of 4 
animals responded to the transplant (decreased rotations by about 60%).  One animal 
in the 12 week survival group decreased rotations by 90%.  In contrast, in this 
experiment, the PD animals that were not transplanted with UCMS cells all showed a 
progressive degradation in performance following 6-OHDA.  Behavior of the non-
responder animals and the control animals was not significantly different. 
Histological assessment of 6-OHDA lesion 
Unilateral staining of TH in the dopaminergic (DA) neurons of SN and VTA on the 
contralateral side of the lesion shows the evidence of the toxic effect of 6-OHDA on the 
DA neurons of the ipsilateral side of the injection site (see figure 3.5, panel A).  The loss 
of DA neurons is restricted to the SN and VTA.  In addition, unilateral TH staining was  
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Figure 3.4:  Effect of HUCMS cells on PD disease.  LEFT: Apomorphine-induced 
rotations (percent change after transplantation surgery) in animals that received HUCM 
or sham transplants. The number of rotations made at the time of transplantation is 
taken as 100%.  A significant decrease in the number of rotations was observe in the 
PD model rats (6-OHDA) that received HUCMS cell transplant compared to the control 
PD rats, that received saline injection. The lesion control rats (no lesion), both with 
HUCM cell transplant or saline injection, did not show rotatory behavior.  RIGHT:  
Inspection of the rotatory behavior of individual PD model rats that received HUCMS 
cells revealed two populations:  One population decreased their rotations (responders, 
indicated in box), the other population did not.  Note that at 6 weeks, 2 of 4 rats 
responded and at 12 weeks, 3 of 4 rats responded to HUCMS cell transplant. 
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observed in the striatum indicating that the ipsilateral nigro-striatal tract is destroyed by 
6-OHDA (not shown).  Figure 3.5 (panel A) shows the TH-staining from the 
experimental groups at the short and long survival period.  In the PD model rats, 6 
weeks after human UCMS cell transplantation there was no TH-positive staining in the 
ipsilateral SN and VTA, and a slight degree of TH-immunoreactivity was observed at 12 
weeks after transplantation (Fig. 3.5, panel A lower left).  The PD model rats that 
received sham transplant did not show any changes in TH staining for TH at the longer 
survival period.  In intact, non-PD model rats with or without UCMS cell-transplant, TH 
staining was observed in SN and VTA at both survival periods and no enhanced TH 
staining was observed around the transplant site (data not shown). 
 
Counting TH-stained cells 
We quantified the number of TH-positive cells in SN and VTA; these results are shown 
in figure 3.5 (panel B).  There is a correlation with the behavioral recovery at twelve 
weeks, but not six weeks following surgery.  At six weeks, there was no effect of the 
transplant on the number of TH cells in the SN or VTA on either the ipsi- or contralateral 
side (see figure 3.5, panel B).  In contrast, at 12 week survival, the animals that 
responded to the transplant had significantly more TH stained cells in the SN and VTA  
ipsi- and contralateral to the transplant.  In the non-responder animals, there was no 
difference in the numbers of TH-stained cells compared with the sham transplanted 
controls.   
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Figure 3.5: Effect of transplant on tyrosine hydroxylase staining.  Panel A: 
Immunocytochemical staining for tyrosine hydroxylase in ipsi- (left) and contralateral 
(right) SN/VTA of transplanted and control animals at 6 week (top) and 12 week 
(bottom) survival periods.  Panel B:  Effect of HUCMS cell transplant on the number of 
tyrosine hydroxylase-positive (TH-positive) cells in midbrain of PD model animals.  
LEFT:  In responder animals (animals demonstrating behavioral recovery following 
HUCMS cell transplant), but not in control animals or in non-responder animals, more 
TH-positive cells were found in the ipsilateral (LEFT) and contralateral (RIGHT) side 12 
weeks following transplantation.  This largest effect was seen in SN, but increases were 
also seen in VTA (data not shown).  
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Recovery of the transplanted cells 
Human UCMS cells were recovered 2 days following transplantation by staining the 
brain sections with anti-human nuclear (AHN) antigen (see supplemental Fig. 3.4, left).  
However, no positive staining human cells were found at 6-weeks or 12-weeks following 
UCMS cell-transplant.    
 
Immune-cell infiltration 
One set of brain sections from selected animals of 6-week and 12-week survival groups 
were stained with anti-CD8 antibody (recognizes T-cytotoxic cells) and visualized by 
AMCA.  Brightly stained CD-8 cells were seen in the lesion site (supplemental Fig. 3.4, 
right), but not in the transplantation site.  Similar staining was observed with CD-4 
(recognizes T-helper cells) and CD11b (recognizes activated microglial cells) 
antibodies. 
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Supplemental Figure 3.4: Immunocytochemical staining for human nuclei (LEFT) and 
host immune cells (RIGHT).  LEFT:  Two days following transplanting 50,000 HUCMS 
cells, many cells positively stained for human nuclear antigen were recovered 
surrounding the injection site.  In contrast, no staining was found in the animals that 
received 1,000 HUCMS cells 6 or 12 weeks following transplantation.  This observation 
suggested that the transplanted cells may be cleared by the host=s immune system.   
(RIGHT)  To investigate the role of the host immune system, the brain sections 
surrounding the transplant and the lesion site were stained for immune cells (CD4, CD8, 
CD11b).   From previous work (see background), we speculated that the immune 
response would be apparent at 6 weeks.  Very few immune cells were detected in the 
transplantation site, more were found in the lesion site (CD8-positive cells shown at 
right). 
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Discussion 
Here, human umbilical cord matrix cells were characterized in vitro and tested for their 
therapeutic potential in a Parkinson=s Disease rodent model. Three novel observations 
were made.  First, UCMS cells have surface markers that indicate that they maybe a 
primitive MSC population.  Second, UCMS cells express genes found in early 
development and genes associated with the three principal germinal layers, e.g., 
ectoderm, mesoderm and endoderm.  Third, UCMS cells can reverse partially the 
Parkinsonian behavioral phenotype in rats.  Taken together, these results suggest that 
the umbilical cord matrix may be an important, non-controversial source of primitive 
stem cells that may be harvested at low cost and in large numbers for cryogenic 
banking. 
 
During development, primordial germ cells and hematopoietic cells migrate from the 
secondary yolk sac through the umbilical region into the embryo proper.  Thus, the cell 
described here may be germ or hematopoietic type cells that were retained in the 
hyaluronic acid-rich extracellular matrix.  Alternatively, the cell described here may be a 
support cell (stroma cell) like those found adjacent to other stem cells (as is in the bone 
marrow cavity, intestinal crypts, etc).  It is important to note that other labs have isolated 
stem cells from various umbilical or placenta structures as well as the amniotic fluid.  
Clearly, these primitive structures, like umbilical cord blood, are important, non-
controversial sources of stem cells.  From the characterization of the cells derived from 
other sources , e.g., umbilical vein (42,43), perivascular region (22), cord blood 
(8,25,44), amniotic fluid (45,46) and placenta (47-51), we hypothesize the cells 
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described here may be recovered in smaller number and less frequently from other 
primitive fetal structures.(47-51)  Further work will be needed to confirm this hypothesis. 
 
Properties of human UCMS cells. 
Previously we reported that UCMS cells could be started via explant culture of the 
minced cord matrix.  Here we report a more efficient method of starting the cultures via 
enzymatic degradation of the extracellular matrix to release the cells from the 
Wharton=s jelly.  UCMS cells were isolated from 78% of the cords, including two cords 
that were refrigerated for 24 hrs prior to isolation (cells were isolated from one of the two 
refrigerated cords).  Since the improved procedure has been used, the isolation of 
UCMS cells has been 100%.  Many cells are found in the initial extraction from the cord 
and, this provides the opportunity to sort off special populations early on.  Adherent cells 
were obtained, expanded, passaged and could be frozen, thawed and cultured.  The 
attached UCMS cells had fairly uniform morphology that is similar to MSCs isolated 
from bone marrow.  Flow cytometry revealed that 20-30% of low passage UCMS cells 
exclude Hoechst dye. The Hoechst dye exclusion was reduced by verapamil treatment, 
an inhibitor of some of the ABCG protein family.  Flow sorting of Hoechst low (also 
called side population cells) is a technique used to isolate primitive hematopoietic stem 
cells (HSCs) and other stem cells (52,53).  Thus, Hoechst staining, like aldehyde 
dehydrogenase staining, may be a vital staining marker of primitive stem cell 
populations.  Our attempts to further enrich a primitive population by flow sorting and in 
vitro expansion was only partially successful: after five passages we failed to increase in 
the number of SP cells beyond 32%.  This suggests that the current culture conditions 
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can not maintain UCMS cells in the most primitive state or, perhaps, some factor  is 
needed to maintain the undifferentiated state.  Work by Sarugaser et al. on perivascular 
umbilical cord cells suggested that their grown was regulated by paracrine factors (22).  
In contrast to what is found with UCMS cell culture, the percentage of population (SP) 
cells in Lin- adult peripheral blood is about 0.1% (54) and the percentage in 
unfractionated umbilical cord blood is about 0.2% (53).  Thus, cord matrix has the 
highest percentage of side population cells known (ranging from 8-32%).  Flow 
cytometry of the UCMS cells revealed about 85% of UCMS cells stain CD44, the 
hyaluronic acid (HA) receptor.  CD44 is a marker found on other stem cell populations 
including MSCs and neural stem cells.   
 
Flow cytometric analysis indicates that UCMS cells have MSC markers.   
As reported by Pittenger et al.(55) and subsequently by others, MSCs have a 
characteristic set of surface markers including cluster of differentiation makers (CD), for 
example, CD29, CD44, CD71, CD90. The consensus marker set for MSCs include SH2 
(endoglin, CD105), SH3 (CD73). UCMS cells have many but not all the surface markers  
on adult MSCs.  For example, UCMS cells stain for CD13, CD29, CD44, CD90, and 
CD10.  In contrast, UCMS cells do not stain (or stain at a low proportion) for SH2 
(average of 7%, range of 3-15%), or CD49e (average of 4%), or HLA-I (43%).  
Saraugauser et al. (22) reported that perivascular cells isolated from the umbilical cord 
had higher expression of SH2 and SH3 antigens compared to what we report here.  
This difference may be due to the different growth conditions used between the two 
laboratories, differences in the antibodies used, or technical differences in gating.  
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Alternatively, two different populations of cells are isolated (as suggested by 
Sarugauser et al.).  To summarize, a significant percentage of UCMS cells lack surface 
markers found on bone marrow derived MSCs, e.g., SH2 and HLA-1.  This suggests 
that UCMS cells may be a more primitive population of MSC cell and are perhaps 
similar to the more rare multipotent adult progenitor cell described by Verfaillie=s lab at 
the University of Minnesota (9,10).   
 
RT-PCR results. 
UCMS cells are pleiotropic, expressing many genes, such as those found in ESCs and 
other primitive stem cells, and genetic markers of all three germ layers, ectoderm, 
endoderm and mesoderm.  This finding is similar to what has been reported for other 
primitive stem cells and suggests that gene silencing or DNA methylation maybe 
important mechanisms to regulating UCMS differentiation.  Currently, we have no data 
to address the mechanisms regulating UCMS differentiation. 
 
Gene Array results 
Of the 50 most highly expressed genes, the genes expressed by UCMS cells fall 
roughly into several categories: those associated with the undifferentiated state of 
ESCs, extracellular adhesion molecules, neurotrophic effects, morphogenesis and 
those associated with the three germ layers.  Mesenchymal cells derived from umbilical 
cord blood have recently been analyzed by microarray and express genes often found 
in mesenchymal stem cells derived from other sources (56,57).  Technical differences 
such as media used to expand the cells, length of time in culture, differences in gene 
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array methodologies prevent the comparison of extant data sets.  Such difficulties have 
been noted previously.  To our thinking, comparisons of gene array data are best made 
from data collected within a single laboratory until such time that there is agreement on 
standardized media, serum, growth conditions, etc. 
 
Transplantation of UCMS into PD rats 
As widely reported previously, unilateral injection of  6-OHDA into the medial forebrain 
bundle caused destruction of the nigrostriatal dopaminergic neurons in the ipsilateral SN 
and VTA.  This destruction produced motor abnormalities analogous to those seen in 
Parkinson=s disease (PD).  The hemi-parkinsonian rats had motor deficits indicated by 
rotatory behavior following apomorphine injection.  The rats had to meet a criterion of 
200 apomorphine-induced rotations for inclusion in our experiment.  The groups were 
randomly divided into those that received a transplantation of hUCMS cells and a 
control group.  Approximately 1000 hUCMS cells were transplanted into PD model rats 
in a single day from a single aliquot of freshly prepared cells.  None of the animals 
received immunosuppression therapy because our preliminary work where we 
transplanted pig UCMS cells showed that the transplanted cells were not rejected 
(31,32).  Moreover, pig UCMS cells survived and proliferated up to 8 weeks after 
transplantation.   
 
Here, the transplanted animals showed a significant recovery as a group.  As 
individuals, when the data was inspected post hoc, it was revealed that more than 50% 
of the transplanted animals demonstrated a behavioral recovery of about 50% reduction 
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in the rotatory behavior.  One of the animals showed a greater reduction of rotatory 
behavior.  Following sacrifice, immunocytochemistry for TH revealed no changes in the 
number of cells in the SN or VTA at six week survival periodB this is despite the fact 
that behavior recovery was observed and accounting for the animals that responded to 
the transplantation.  In contrast, the responding transplanted animals that survived 12 
weeks, there was a significant increase in the number of TH-stained cells recovered in 
the SN and VTA.  Most interestingly, the number of TH-stained cells was increased 
ipsilateral and contralateral to the lesioned nigrostriatal pathway. The mechanism that 
underlies this observation is unknown.  Hypothetically, a rescue of dying nigrostriatal TH 
neurons may be stimulated by growth and neurotrophic factors released by the UCMS 
cells transplant.  The hUCMS cells produce significant amounts of GDNF (figure 3.4), 
one of the most potent trophic factors for dopaminergic neurons, and fibroblast growth 
factor 20 (table 3.3), which is thought to be an important survival factor for dopaminergic 
neurons that is preferentially expressed in rat brain substantia nigra (58). On the other 
hand, UCMS cells may have properties similar to bone marrow stromal MSCs to inhibit 
the host immune response.  Dampening the host immune response may limit secondary 
damage and permit moribund neurons to recover.   
 
We could not recover the transplanted hUCMS cells; the various reasons for this could 
be 1. The graft cells are cleared by the host immune system and 2. The low-density 
graft was not able to support itself and the cells could not survive for long time.  Due to 
the fact that we found immune cells at the lesion site, but not the transplantation site, it 
is not clear if the transplanted cells were scavenged by immune cells.  Although, there is 
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a possibility that the transplanted cells were cleared and the immune cells left the area, 
as previous work with fetal pig mesencephalic tissue grafted into the rat brain indicates 
that the grafted tissue is rejected in about 4-6 weeks (59).  We have not direct or 
indirect evidence for a host immune response to the transplanted cells.   
 
That the low-density graft was not recovered may also be due to death of the grafted 
cells.  Again, we have no direct evidence that the graft cells died, e.g., there was no 
cellular debris, increase astrocyte infiltration, etc, that would indicate that the graft cells 
died.  That we can recover human graft cells up to one week following transplantation 
and recover pig umbilical cord matrix cell micrograft up to 8 weeks following 
transplantation into rat (31,32) suggests that our transplantation protocols are 
responsible for the problems recovering the grafted cells.  
 
We observed a significant decrease in apomorphine-induced rotations in the PD model 
rats.  There was a significant decrease in the number of rotations 4 weeks following 
transplantation that continued to 12 weeks after transplantation.  Irrespective of the 
survival period, out of 8 PD models that were transplanted with hUCMS cells, 4 animals  
showed 40-50% decrease in number of rotations, 1 animal showed 90% decrease and 
3 did not respond.  The 3 animals that did not respond to the transplantation therapy 
showed a slight increase in the number of rotations, which can be attributed to the 
clearance of the graft cells earlier than the others.  The TH-positive DA neurons in SN 
and VTA show a valid correlation between the number of cells and apomorphine-
induced rotations i.e. more the number of TH-positive cells in SN and VTA lesser the 
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number of rotations.  Therefore, the behavioral recovery of the PD model animals could 
be due to rescue of the degenerating DA neurons of SN and VTA, which could be 
mediated by various trophic factors (60-63).  Further analysis is due to prove this 
hypothesis.  The above data from UCMS cells indicate that these cells may be 
therapeutically useful in treating central nervous system disorders. 
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Abstract 
Parkinson’s disease (PD) is a neurodegenerative disorder of central nervous 
system, where stem cells are deemed to have a potential therapeutic benefit by 
regenerating or protecting the degenerating neurons.  Previously, Human 
umbilical cord matrix stem (hUCMS) cells, which are a type of mesenchymal 
stem cells, were shown to have a therapeutic benefit in PD model rats.  Here, we 
investigated the dose-dependent effect of hUCMS cells in PD model rats.  PD 
model rats were created by administering 6-hydroxydopamine (6-OHDA) 
stereotaxically into the left medial forebrain bundle.  Four weeks after the 6-
OHDA lesion, rats received about 2500 and 25000 hUCMS cells (or sham 
transplants).  The rats did not receive immunosuppressive therapy.  
Apomorphine-induced rotatory behavior was used to analyze the motor deficits of 
the PD-model rats.  When data was pooled from the previous study with 1000 
hUCMS cell transplant, there was a significant dose-dependent decrease in 
apomorphine-induced rotations overtime up to 10 weeks after transplantation.  A 
few graft cells were recovered at 1-week post-transplantation, but none were 
recovered at 6-weeks or 10-weeks.  In a pilot experiment with hUCMS cell 
transplantation in immunosuppressed rats, the graft was recovered at 1-week 
post-transplantation.  Quantitative assessment of the TH-positive neurons in 
substantia nigra (SN) and ventral tegmental area (VTA) revealed that there is no 
significant difference in the number of dopaminergic neurons on the lesioned side 
in the rats that received hUCMS cell transplant compared to the control rats.  A 
novel quantitative measure has been introduced to evaluate the transplant 
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efficacy (Transplant or T-value), where multiple parameters are taken into 
consideration.  The T-value correlates well with the behavioral recovery in the 
various groups.  These results show that it is likely that the hUCM cells may play 
a role in promoting improvement of motor deficits in PD-model rats, but the 
mechanism is currently unknown. 
 
Keywords: umbilical cord matrix, stem cells, xenotransplantation, Parkinson’s 
disease, 6-hydroxydopamine, apomorphine, tyrosine hydroxylase,  
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Introduction: 
Parkinson’s disease (PD) is the second most common age-related 
neurodegenerative disease, and is the most common neurodegenerative 
movement disorder (Dawson and Dawson, 2003).  It affects 1% of the U.S. 
population older than 65 and an estimated 60,000 new cases are being 
diagnosed annually.  There is no cure for the disease, but symptomatic treatment 
using L-DOPA or carbidopa alleviate some of the symptoms early in the disease 
(Arenas, 2002).  However, as the disease progresses treatment effectiveness 
decreases and drug-induced dyskinesias appear (Obeso et al., 2000b;Obeso et 
al., 2000c).   Another approach often combined with L-DOPA and carbidopa is 
deep brain stimulation of the globus pallidus and the subthalamic nuclei (Arenas, 
2002;Obeso et al., 2000a).   Thus, the study of pathologic mechanisms and 
therapeutic alternatives of PD utilizing animal models is very critical.  There are 
several rodent models of PD (Beal, 2001); 6-hydroxydpamine (6-OHDA) model 
being one of the most commonly used models.  A chronic 6-OHDA model with 
progressive degeneration of the DA neurons is described by Sauer and Oertel 
(Sauer and Oertel, 1994) that may more closely mimic the disease than the acute 
models.  
 
The therapy of acute and chronic neurological disorders would be significantly 
enhanced with stem cells endowed with the ability to form several kinds of 
neurons or glia that can be used to replace the damaged neural cells (Bjorklund 
and Lindvall, 2000;Bjorklund et al., 2000).  Neural stem cell populations have 
been identified as ependymal cells (Johansson et al., 1999b;Johansson et al., 
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1999a), subventricular zone astrocytes (Doetsch et al., 1999), and cells in the 
subgranular zone of the dentate gyrus (Gage et al., 1998).  Thus, harvesting 
neural stem cells from the human patient cannot be done easily because the 
location and distribution of the neural stem cells makes it difficult to harvest a 
substantial population of these cells for in vitro expansion/manipulation and 
subsequent autologous transplantation.  Moreover, the role of endogenous 
neural stem cells in disease is not clear.  Therefore, to treat PD, a motor disease 
characterized by loss of neural catecholaminergic input to the striatum, several 
different therapeutic approaches have ensued.  The most radical approach is the 
transplantation of human or porcine fetal neural tissue into human brains 
(Bjorklund and Lindvall, 2000;Deacon et al., 1997).  Embryonic stem (ES) cells 
and the dopaminergic neurons derived from ES cells were shown to be effective 
in treating animal models of PD (Bjorklund et al., 2002;Kim et al., 2002).  Graft 
versus host disease (GVHD) and host immune rejection are serious problems 
associated with cell therapy including xenotransplants (Borlongan et al., 
1996;Duan et al., 1996;Duan et al., 1995).  In addition to cell-replacement, 
regenerative/restorative therapy has gained importance as an effective 
therapeutic strategy in managing neurodegenerative diseases, where rescue or 
restoration of the degenerating neurons is deemed to occur through trophic 
factors, pharmaceutical agents, immunomodulation etc. (Ourednik et al., 
2002;Beal, 2003).  Moreover, glial derived neurotrophic factor (GDNF) has been 
shown to rescue degenerating DA neurons in vitro (Ding et al., 2004), and in vivo 
in PD animal models (Bjorklund et al., 1997;Kirik et al., 2000a).  Also, 
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immunomodulation (Aharoni et al., 2005;Stangel, 2004) and immunoisolation 
(Emerich and Salzberg, 2001) techniques have been shown to have therapeutic 
benefit in neurological diseases. 
 
Umbilical cord matrix (UCM) or Wharton’s jelly, the gelatinous connective tissue 
found in the umbilical cord, is a source of primitive stem cells.  In culture, these 
cells express stem cell characteristics (Mitchell et al., 2003;Weiss et al., 2005).  
Our previous work revealed that pUCMS cells express stem cell markers and can 
be grown in vitro for more than 100 population doublings and differentiate into 
neuron-like cells in vitro and in vivo (Mitchell et al., 2003;Weiss et al., 2003).  
Recently, Human UCMS cells were characterized and their surface antigen and 
gene profile closely resembles to that of mesenchymal stem cells (Weiss et al., 
2005).  Also, a subset of hUCM cells respond to the differentiation signals in vitro 
and exhibit neuronal characteristics (Mitchell et al., 2003;Weiss et al., 2005).  In 
addition, when transplanted at a low-density, hUCMS cells provide therapeutic 
benefit in PD model rats owing to the restoration of degenerating DA neurons in 
SN and VTA (Weiss et al., 2005). 
 
Assessing the therapeutic value of cell transplantation is becoming critical to 
determine the optimal cell type and intervention (Lindvall et al., 2004).  A 
universal metric for assessing the transplant may include components of the 
behavior/physiological and morphological outcomes and the host immune 
response and long term engraftment.  Here, we introduce such a metric, referred 
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to as “Transplant or T-value”, which evaluates the efficacy of the transplanted 
cells by considering multiple parameters of the graft (survival, proliferation, 
differentiation and tumorigenecity), and host (behavior, health status and immune 
response.)  
 
As a follow-up to our previous study (Weiss et al., 2005), the PD model rats 
received a medium-density (approximately 2500 hUCMS cells) or high-density 
(approximately 25,000 hUCMS cells) transplant.  When the rotatory behavioral 
data was pooled from the previous study, there was a significant dose-dependent 
reduction in the apomorphine-induced rotations in the PD model animals that 
received hUCMS cell transplant compared to the control animals (PBS infusion).  
However, the transplanted hUCMS cells were not recovered either at 6 weeks or 
10 weeks after transplantation.  We hypothesize that the transplanted hUCMS 
cells have a dose-dependent therapeutic benefit by restoring, but not replacing, 
the host dopaminergic neurons in PD model rats, resulting in recovery in the 
motor deficit (apomorphine-induced rotatory behavior). 
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Materials and Methods: 
 
Cell culture and counting 
Human UCMS cells were generated and expanded as described previously 
(Weiss et al., 2005).  Briefly, Human UCM cells were harvested from the human 
umbilical cords by using enzymes, such as Hyaluronidase 1mg/ml (Sigma H-
2126) and Collagenase 300units/ml (Sigma C-6885).  The hUCM cells were 
cultured and maintained as described previously (Medicetty et al., 2004;Weiss et 
al., 2005) in a defined media containing 56% low glucose DMEM (Invitrogen 
11885-092), 37% MCDB 201 (sigma M6770), 1% 100x Insulin-Transferrin-
Selenium (Invitrogen 51500056), 1% 100x Albumax1 (Invitrogen 11020021), 
0.001% 10-4 M Dexamethasone (Sigma D4902), 1% 10-2 M Ascorbic acid-2 
phosphate (sigma A8960), 1% Antibiotic/Antimycotic (Invitrogen 15240-062), 2% 
FCS (Hyclone-heat inactivated), 0.001% Epidermal growth factor (R&D 236-EG-
200), 0.2% Platelet-derived growth factor (R&D 520-BB-050).  Cells from the 
same cord and passage (P4) were used for transplantation in all the animals.  
Before transplantation, the cells were lifted by a trypsin solution (0.05%) and 
counted by a hemocytometer, and were adjusted to a final concentration of 
approximately 2500 and 25,000 cells per microliter.  The cell concentration was 
confirmed before and after the injection to ensure that the correct numbers of 
cells are delivered. 
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6-hydroxydopamine (6-OHDA) lesion and behavioral assesment 
PD model rats were created by stereotaxic injection of 6-hydroxydopamine (6-
OHDA) as previously described (Weiss et al., 2005;Ungerstedt and Arbuthnott, 
1970).  Anesthetized female Sprague-Dawley rats received a 4.0 µl injection of 
32 mM 6-OHDA HCl (Sigma) dissolved in 0.02% ascorbate at 1 µl/min into the 
left medial forebrain bundle (Bregma -2.8; lateral 2.0; ventral 8.4mm) or an 
injection of  vehicle (sterile PBS) four weeks prior to transplantation.  Following 
surgery, rats were monitored for behavioral changes, weight loss and overall 
health.  Four weeks following lesion surgery the animals received the human 
UCM cell transplant or sham transplant (sterile saline).  The rats were placed in 
an opaque testing chamber and allowed to acclimate for 5 minutes prior to 
assessing the number of rotations in a 30 minute period after apomorphine 
injection (alternate weeks, 0.1 mg/kg, sc).  The lesioned rats that did not exhibit 
at least 200 contralateral rotations/30 minutes after apomorphine treatment were 
excluded from the experiment.  Further, apomorphine-induced rotations were 
measured at alternate weeks till the end of the experimental period.  Based on 
the difference in the number of apomorphine-induced rotations at the end of 
survival period and the baseline rotations (number of rotations at the time of 
transplantation), the animals that received hUCMS cell transplant are designated 
as either 1. Responder – decrease and 2. Non-responder – no change or 
increase in the number of rotations compared to the baseline (see supplementary 
table 4.1). 
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Immunesuppression  
The rats were treated by using cyclosporin A (CsA, 10mg/kg, ip) in Cremophor - 
ethanol vehicle (1 ml/kg, ip) daily, starting 2 days prior to transplantation of 
hUCMS cells. In addition, the rats received 20 mg/kg methylprednisolone (Solu-
Medrol; Pharmacia-Upjohn) for the first four days following surgery.  These 
methods have been shown to effectively protect pig neural grafts from immune 
rejection in the rat brain (Borlongan et al., 1996;Wennberg et al., 2001) 
 
 
Transplantation of hUCMS cells 
Human UCM cells were transplanted into anesthetized rats (2% halothane in 
oxygen) via stereotaxic injection into the left striatum (Bregma +0.5, Lateral 3.4, 
Ventral 5.0 mm from the surface of the brain).  Four weeks after 6-OHDA 
injection, approximately 2500 and 25,000 hUCM cells in 1ul of the sterile saline 
were injected over 5 min.  The control group received sham transplantation 
(PBS).  At 6 and 10 weeks post-transplantation, rats were randomly selected 
from various groups, anesthetized and sacrificed by transcardial perfusion with 
heparinized isotonic saline rinse followed by 10% buffered neutral formalin. The 
brains were removed, postfixed, and cryoprotected in 20% sucrose overnight.  
Frozen sections of the brains were cut coronally at 40 µm and the sections were 
collected into six sets of adjacent sections, each set consisting of every sixth 
serial section.   
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Tissue processing and Immunocytochemical processing (IC)  
Immunocytochemical (IC) detection of a single antigen was performed on one set 
of sections as previously described (Weiss et al., 2003) and the adjacent sets of 
sections were held in reserve in a cryoprotectant solution (Watson, Jr. et al., 
1986).  The free-floating tissue sections were stained with primary antibodies for 
anti-human nuclear antigen (mouse host, 1:30, Chemicon), anti-human 
mitochondria (mouse host, 1:100, Chemicon) anti-TH (rabbit host, 1:2000, East 
Acres Biologicals), anti-rat CD-4 (mouse host, 1:500, Serotec), anti-rat CD-8 
(mouse host, 1:500, Serotec), anti-rat CD-11b (mouse host, 1:250, serotec), anti-
rat CD-161(mouse host, 1:250, Serotec).  The antigens were visualized either 
with diaminobenzidine (DAB) and hydrogen peroxide using a commercially 
available ABC kit (Vectastain) or with immunofluorescence.  For 
immunofluorescence localization, either anti-mouse alexa488 (Molecular probes, 
1:200) or 7-amino-4-methylcoumarine-3-acetic acid (AMCA) - Avidin D (Vector 
Laboratories, 1:200) was used with the biotinylated secondary antibody.  The IC-
stained sections were mounted on subbed microscope slides, air-dried, and 
rinsed with distilled water.  To detect the immunofluorescence, the sections were 
observed using epifluorescence illumination with the appropriate filter 
combinations on a Leica DMRD microscope after clearing and coverslipping with 
glycerol containing N-propyl gallate (3 parts 2% N-propyl gallate in 0.1M Tris 
buffer, pH 9.0 and 7 parts glycerol).   
 
 136 
 
Quantification of TH-positive cells in SN and VTA 
The TH-positive DA neurons in substantia nigra (SN) and ventral tegmental area 
(VTA) were quantified by using a design-based unbiased stereological method by 
using a morphometry/image analysis system (Bioquant Nova Prime, R&M 
Biometrics).  One set of brain sections of all the experimental animals were 
stained with anti-TH antibody and visualized with DAB.  In each section the 
region of interest is outlined (SN and VTA), and the number of TH-positive cells 
per sq. mm. of that region were selected and semi-automatically counted.  All the 
sections in the particular set, containing SN and VTA were screened and TH-
postive cells were counted, and the average number of TH-positive DA neurons 
per sq. mm. was calculated for each animal  
 
Statistical analysis 
Recovery of function (apomorphine-induced rotations) were evaluated over time 
(repeated measures) at alternate weeks till the end of the experiment and pooled 
across groups to compare treatments.  All tissue manipulations were conducted 
in large batches to avoid batch to batch differences in tissue IC-staining.  Tissue 
processing and data collection were conducted in an experimenter-blind fashion.  
After measurements and counting, the survival group status was decoded prior to 
statistical analysis.    In general, analysis of variance (ANOVA) was used to 
evaluate group differences.  ANOVA was followed by post hoc testing using 
 137 
Scheffe=s test.  Significance was set at p<0.05. The mean plus or minus one 
standard error are presented on graphs. 
 
Transplant value (T-Value) of the graft: 
The formula used for calculating the transplant (T) value and explanation are:  
T value = 2F + G + H, where F = functional efficacy; G = graft outcome; H = host 
tolerance.  
 
To calculate the T-value for animals from all the groups (low, medium and high-
density graft) of both trials, the required parameters (see below) were collected 
for each animal.  Every term in the equation for F, G and H was expressed as a 
score of 1-10 assigned in the following way.  For each parameter, the range 
(minimum and maximum value) was divided into 10 equal sets, and range 
assignments (1-10) were made and represented as a score for that particular 
parameter.  The individual parameter score is then put into the formula.  Each 
term was expressed so that the proportionality is correct as shown in the formula.  
Further, the T-value is mapped against the behavioral recovery to test the 
correlation. 
 
Based on the type of parameter, desirable or undesirable, we assigned the best 
score ‘10’ to the highest group (maximum value of the range) or lowest group 
(minimum value of the range) respectively.  For example, supplementary table 
4.2 shows the scoring for the % change in weight, a desirable parameter that 
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indicates the health status of the animal.  F (functional efficacy) = % baseline 
rotation score ('10' = lowest group) + TH cells in SN ('10' = highest group) + 
mortality ('10' = lowest group) + weight loss from transplant to sac ('10' = lowest 
group) + ipsilateral rotations after apomorphine ('10' = lowest group).  G (graft 
outcome) = % donor cells apoptotic ('10' = lowest group) + incidences of tumor 
('10' = lowest group) + % donor cells expressing neuronal markers ('10' = highest 
group) + % donor cells expressing glial markers ('10' = highest group).  H (host 
tolerance) = number of infiltrating CD8 cells ('10' = lowest group).   
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Results: 
 
 
Behavioral assessment of the PD model rats 
Previously, we have confirmed the effects of 6-OHDA in rat brain by 
immunostaining for TH, which validates this PD model (Weiss et al., 2005).  The 
rotatory behavior of the PD model rats was assessed by counting the 
apomorphine-induced rotations for 30 minutes at alternate weeks till the end of 
the experimental period.  Half the experimental animals were sacrificed 6-weeks 
following transplantation and the remaining were sacrificed at the end of 
experimental period i.e. 10 weeks post-transplantation.  In the previous trial, we 
have reported the detailed rotatory behavior analysis of the PD model rats that 
were transplanted with 1000 hUCMS cells (Weiss et al., 2005).  Here, owing to 
the fact that the controls in both the trials were statistically not different (data not 
shown), we pooled the data from the low-density transplant with the data from 
the medium-density and high-density transplant to study the dose-dependent 
effect of hUCMS cells.  The PD model rats that received the hUCMS cell 
transplant, except for the high-density transplant group, showed a significant 
dose-dependent decrease in the number of rotations compared to the sham 
transplanted (PBS) animals (see Fig. 4.1).  In the first trial (1000 cells), 5 of the 8 
animals responded to the transplant i.e. decreased their apomorphine-induced 
rotation behavior.  In the second trial, 6 of 13 animals treated with 2500 cells and 
6 of 12 animals treated with 25,000 cells responded (see methods section for 
description of a ‘responder’). Thus, approximately 50% of the animals respond to 
hUCMS cell treatment.  Although half of the rats in the high-density transplant  
 140 
 
40
60
80
100
120
140
160
0 2 4 6 8 10
control
2500
25,000
1000
Weeks after transplant
 
 
 
Figure 4.1: Effect of human umbilical cord matrix stem (hUCMS) cell transplant 
on apomorphine-induced rotation behavior.  The data from first trial is pooled with 
data from second trial. In the first trial, 5 of the 8 animals responded to the 
transplant, e.g., decreased their apomorphine-induced rotation behavior.  In the 
second trial, 6 of 13 animals treated with 2500 cells and 6 of 12 animals treated 
with 25000 cells responded. Thus, approximately 50% of the animals respond to 
UCM treatment. 
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group responded to hUCMS cell transplantation (see supplementary table 4.1), 
as a group they are not statistically different from the control group. 
Recovery of the graft cells 
The transplanted hUCMS cells were recovered by staining the brain sections with 
anti-human nuclear (AHN) antigen or antibody to human mitochondria.  Very few 
graft (hUCM) cells were recovered at 1 week following transplantation in non-
immunosuppressed PD model rats (Fig. 4.2A shows the nuclei of the 
transplanted hUCM cells stained with AHN antigen and visualized with alexa 
488).  However, the 6 and 10-week survival animals that received 2500 and 
25000 hUCM cell-transplant did not show any positive staining for AHN antibody.   
In addition, hUCMS cells (high-density, 25000) that were transplanted into 
immunosuppressed rats were recovered at 1-week post-transplantion (Fig. 4.2B 
shows anti-human mitochondrial staining visualized with alexa 488) and few 
transplanted cells diffused from injection site into the brain parenchyma (data not 
shown). 
Assessment of immune-cell infiltration 
Brain sections from 1, 6 and 10-week animals with 2500 and 25000 cell-graft 
were stained with rat anti-CD8 antibody (recognizes T-cytotoxic cells) and 
visualized by AMCA.  There were no rat CD-8 positive cells at the transplantation 
site in any of the groups, which is similar to what we have noticed earlier with 
1000-cell transplant (Weiss et al., 2005).  However, there were rat CD11b-
positive 
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Figure 4.2:  (A-B) Recovery of graft cells.  Transplanted hUCMS cells were 
recovered at 1-week following transplantation in non-immunesuppressed rats by 
immunostaining for anti-human nuclear antigen (arrows in A) and in 
immunosuppressed rats by immunostaining for anti-human mitochondria (B) 
localized with Alexa 488.  Activated microglia (identified by CD-11b staining) are 
noticed at the graft site (C), localized by AMCA.   
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(recognizes activated microglia) cells at the transplant site in the 1-week survival 
animals (See Fig. 4.2C). There is no staining for rat CD-4 (recognizes T-helper 
cells) or rat CD-161 (recognizes natural-killer cells) at the transplant site in the 1-
week survival animals.   
 
TH- staining and Quantification of DA neurons in SN and VTA 
One set of brain sections of all the 6 and 10-week experimental animals were 
stained with anti-TH antibody and visualized with DAB. Figure 4.3A-F shows the 
TH-staining in SN and VTA from randomly selected representative animals from 
various groups and survival periods.  As expected from the type of the lesion, a 
robust TH-staining (large number of DA neurons) on the non-lesion side (right 
side) and a weak TH-staining (very few DA neurons) is observed in all the groups 
(control, medium-density and high-density transplant) at 6 weeks or 10 weeks 
following transplantation.  Further, the TH-positive cells in SN and VTA of all the 
experimental animals were quantified by semi-automatic counts in Bioquant.  
Statistical analysis of TH-positive cells per sq. mm. in the different groups 
revealed that there is no significant difference between the various groups either 
at 6 or 10 weeks post-transplantation (See Figure 4.4).  
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10-week survival
 
 
Figure 4.3:  Tyrosine hydroxylase (TH) staining in PD model rats with and without 
hUCMS cell transplant.  One set of brain sections from all the experimental 
animals were stained for TH, a catecholaminergic marker.  (A-F) shows sections 
from representative animals from various groups that were selected randomly 
and matched for similar morphology.  Top panel are TH-stained midbrain 
sections of the control (sham-transplant) group at 6-week (A) and 10-week (B) 
post-transplantation.  Middle panel comprises TH-stained sections from the 
medium-density (2500 hUCMS cells) group at 6-week (C) and 10-week (D) post-
transplantation.  The bottom panel consists of TH-stained sections from the high-
density (25,000 hUCMS cells) group at 6-week (E) and 10-week (F) post-
transplantation. 
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Figure 4.4: Quantification of TH-positive DA neurons in SN and VTA.  The TH-
positive cells were counted semi-automatically by a design-based stereological 
method and analyzed through Statview.  There is no significant difference in the 
number TH-positive cells in the ventral midbrain of the control (sham transplant), 
high-density or medium-density hUCMS cell-transplant groups either at 6 weeks 
or 10 weeks after transplantation. (p<0.05)  
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T-value 
The scoring system for calculating T-value is discussed in detail in methods, and 
supplementary table 4.2 shows detailed scoring table for one of the desirable 
parameters, health status, implied by % change in weight over time in the low-
density (1000 hUCMS cell) transplant group.  All the other parameters were also 
assigned a score (1-10) in the similar manner.  As the graft cells were not 
recovered, the G-graft outcome component included only ‘tumour incidence’ 
parameter.  T-values were calculated for all the animals from both trials with all 
the groups (control, low-density, medium-density and high-density transplant) 
and a treatment group mean was calculated at each survival period.  The final T 
score for each transplant condition is the average of those of the survival periods.  
Figure 4.5 demonstrates the validity of the T-value, where it shows a positive 
correlation between T-value and behavioral improvement. 
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Figure 4.5: T- value. Data from all the animals in both trials was used to generate 
T - values. This pilot data reveals that the T-value has merit.  Animals that 
displayed superior improvement behaviorally (indicated here by the change in 
their rotations at sacrifice on x-axis) tended to have a higher T-value (shown on 
the y - axis). 
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Discussion 
 
Several rodent models have been used to study the pathology and therapeutic 
intervention in PD (Beal, 2001), of which the MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyrodine) model and 6-OHDA model are most commonly used.  The 6-
OHDA rodent model is well-known for its unilateral lesions that create a definite 
behavioral phenotype that is easily quantifiable (Beal, 2001).  In addition, a 
chronic 6-OHDA model has been described (Sauer and Oertel, 1994), which 
shows a progressive loss of DA neurons in the ventral midbrain.  The neurotoxin, 
6-OHDA, when injected into medial forebrain bundle causes destruction of the 
dopaminergic neurons in the ipsilateral SN and VTA leading to PD phenotype.  
Previously, we have utilized the 6-OHDA model to asses the therapeutic potential 
of low-density hUCMS cells (Weiss et al., 2005).  The 6-OHDA lesion was 
assessed immunocytochemically by staining the brain sections with an antibody 
against tyrosine hydroxylase (TH), the rate limiting enzyme in dopamine 
synthesis (Kim et al., 2002).  Unilateral staining of TH in the ventral midbrain DA 
neurons and striatum on the contralateral side of the lesion showed the evidence 
of the toxic effect of 6-OHDA on the dopaminergic system (Weiss et al., 2005). 
The degeneration of DA neurons is largely restricted to SN and VTA.  The rats 
were screened based on the apomorphine-induced rotatory behavior for 
transplantation of hUCMS cells.  Apomorphine is a dopamine agonist, which 
stimulates dopamine receptors, activates the receptors on both sides, but greater 
activation on the lesion side because of denervation supersensitivity, leading to 
rotations on contralateral side (Kirik et al., 2000a;Nishimura et al., 2003). 
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Supplementary table 4.1: Summary of apomorphine-induced rotations in PD 
model rats.  The number of apomorphine-induced rotations before 
transplantation is taken as pre-transplant% (baseline – 100%) to compare the 
changes in the rotatory behavior.  The response parameter (R or NR) is only 
assigned to the PD-model rats that received hUCMS cell graft, but not sham graft 
(C).  R (Responder) - decrease in %rotations compared to baseline (pre-
transplant).  NR (Non-responder) - no change or increase in %rotations 
compared to baseline (pre-transplant).  C (Control) - animals that did not receive 
hUCMS cell graft. 
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In the earlier trial, we observed a significant behavioral improvement with a low-
density (approximately 1000) hUCMS cell transplant into the striatum of non-
immune suppressed PD rats, which correlated with increased number of TH-
positive DA neurons in the SN and VTA on the lesioned side (Weiss et al., 2005).  
As the controls from the earlier trial were statistically not different from the 
controls in the current trial, we pooled the behavioral data from the two trials to 
evaluate the effect of graft density on the apomorphine-induced rotations.  When 
the rotatory behavioral data was pooled from the first trial, we observed a dose-
dependent decrease in apomorphine-induced rotations in the PD model rats.  In 
the first trial, 5 of the 8 animals responded to the transplant, i.e. decreased their 
apomorphine-induced rotation behavior.  In the second trial, 6 of 13 animals 
treated with 2500 cells and 6 of 12 animals treated with 25000 cells responded 
(see supplementary table 4.1).  Thus, approximately 50% of the animals respond 
to UCM treatment.  Although half of the rats with high-density transplant showed 
decrease in apomorphine-induced rotations, as a group they were not 
significantly different from the control group.  In addition, some rats in the control 
group show spontaneous improvement in rotatory behavior (supplementary table 
4.1).  However, the intensity of response (% decrease in the number of 
rotations), but not the number of responders, makes the low and medium-density 
transplant groups significantly different from the control group.  Moreover, we 
observed the other desirable parameters, such as health status (represented by 
the increase in body weight), to be lower in the control group compared to other 
groups (see supplementary table 4.2).  Thus, T-value, which considers multiple 
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host and graft parameters, may be a better method to evaluate these PD model 
rats.  In addition, the TH-positive DA neurons in the SN and VTA on the lesion 
side of the medium-density transplant group did not correlate with the behavioral 
improvement, which is different from what we noticed with the low-density 
transplant (Weiss et al., 2005).  Taken together, this data suggests that the low-
density graft may be more beneficial than the medium and high-density grafts.  
 
One of the major issues of xenotransplantation is graft vs host disease (GVDH) 
and immune rejection (Larsson and Widner, 2000;Larsson et al., 2000;Larsson et 
al., 2001).  Here, none of the animals received immune suppression therapy 
because, the results from our preliminary work, where we transplanted pUCM 
cells at various densities, showed that the transplanted cells were not rejected 
(Weiss et al., 2003).  Moreover, when we transplanted 150 pUCM cells in 6-
OHDA lesioned rats, the cells survived and proliferated upto 8 weeks after 
transplantation (Medicetty et al., 2004); based on which we have transplanted 
1000 hUCMS in the first trial, followed by 2500 and 25000 hUCMS cells.  
However, we recovered only a few graft cells in PD model rats at 1-week post-
transplantation, but none at 6-weeks or 10-weeks.  The fact that we were able to 
recover a large number of graft cells in the immunosuppressed rats at 1-week 
post-transplantation suggests that the immune system may play a role in clearing 
the graft cells in non-immunesuppressed rats.  Although the CD-11b positive 
cells (activated microglia) noticed around the graft at 1-week post-transplantation 
in non-immunesuppressed animals may add some credibility to the above  
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Supplementary table 4.2: Scoring method for health status (% change in body 
weight), which was used to calculate T-value along with other parameters.  The 
above table shows the body weight scores for all the animals in the low-density 
(1000 hUCMS cell) transplant group.  Body weight at transplantation is taken as 
the baseline to assess the % change in body weight at the end of the survival 
period.  The range is calculated based on the maximum and minimum % change 
in body weight and further divided into 10 groups with representative scores of 1- 
10.  The animals were assigned a score based on the group they were in.   
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assumption, there were no CD4, CD8 or CD 161 cells identified at the graft site.  
In addition, the absence of CD8 cells at 6 or 10 weeks post-transplantation 
makes it pre-mature to put the blame entirely on the immune system.  It is 
possible that the host immune cells may have cleared the graft cells and left the 
area by 6-weeks, as previous work with fetal pig mesencephalic tissue grafted 
into the rat brain indicates that the grafted tissue is rejected in about 4-6 weeks 
(Larsson et al., 2001).  The other speculation is that the graft was not able to 
support itself and the cells did not survive for long time.   
 
The behavioral recovery of the PD model animals could be due to rescue of the 
degenerating DA neurons of SN and VTA, which could be mediated by various 
trophic factors (Bjorklund et al., 1997;Kirik et al., 2000a;Kirik et al., 
2000b;Yoshimoto et al., 1995;Chen et al., 1995;Fawcett et al., 1995;Haque et al., 
1995).  We have evidence that hUCMS cells produce potent trophic factors such 
as GDNF, VEGF, FGF20 and CNTF (Weiss et al., 2005).  Previously, we 
reported that  40-80% of hUCM cells (depending on the isolate) produce GDNF 
(glial cell line-derived neurotrophic factor) (Weiss et al., 2005), which is a potent 
survival factor  for dopaminergic neurons (Ding et al., 2004;Arenas et al., 
1995;Bjorklund et al., 2000;Helt et al., 2001;Bjorklund et al., 1997).  It has been 
shown that stem cells may promote neuroprotection by immunomodulation 
(Pluchino et al., 2005b;Pluchino et al., 2005a), which could be another cause for 
the behavioral improvement in this PD model rats.  Recently, Ryan et al. reported 
that mesenchymal stem cells may evade the allogenic host immune response by, 
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1. hypoimmunogenecity, 2. preventing T-cell response by dendritic cell 
modulation and 3. inducing a local immunosuppressive milieu (Ryan et al., 2005).  
Preliminary data from our lab shows that hUCMS cells express HLA-G 
(manuscript in preparation), which is an MHC-like protein present at the feto-
maternal interface and is shown to have immunosuppressive capabilities (Rouas-
Freiss et al., 2000;Rouas-Freiss et al., 1999).  In addition, hUCMS cells seem to 
dampen the proliferative potential of mitogen-stimulated splenocytes (manuscript 
in preparation).  We hope to elaborate on the immunosuppressive abilities of 
hUCMS cells with ongoing work in our lab. 
 
It is critical to have a universal metric to assess and optimize the cell transplants, 
where multiple parameters of both the host and the graft are taken into 
consideration (Lindvall et al., 2004).  Here, we introduced a new universal metric, 
Transplant or T-value, to asses the effect of hUCMS cell transplants on PD 
model rats.  In both the trials, as we could not recover the graft cells at 6, 10 or 
12 weeks post-transplantation, the graft outcome ‘G’ had only the ‘tumor 
incidence’ component.  Here, the T-value is shown to be a useful metric by its 
positive correlation with the behavioral recovery.  The T-value can be used to 
compare between cell-type or cell-number and other experimental variables, 
such as immune suppression.  Theoretically, the T value could be adapted for 
any type of transplantable cell or disease model.  In future studies, we intend to 
use the T-value to optimize hUCMS cell transplantation in PD rats, and to 
investigate possible mechanisms whereby hUCMS cells mediate their effects.   
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Transplantation of hUCM cells showed a dose-dependent behavioral recovery in 
the PD model rats.  Based on our work in progress (data not shown), we suggest 
two likely mechanisms for the behavioral improvement and increased survival of 
DA neurons in the SN and VTA: 1. Trophic rescue via factors such as GDNF or 
2.  Decreased neuroinflammation due to immune suppression by hUCM cells.  
We intend to utilize an in vitro PD model (6-OHDA treated PC-12 cells) (Ha et al., 
2003;Ryu et al., 2002;Tarabin and Schwaninger, 2004) free of immune cells to 
elucidate possible trophic effects of hUCMS cells, and in vitro immune function 
assays (Djouad et al., 2003;Le et al., 2004;Pittenger et al., 1999) to determine 
whether hUCM cells are immunesuppressive.   Our preliminary in vitro work 
reveals that hUCMS cells are immunesuppressive (manuscript in preparation).  
Given the fact that a large number of graft cells were recovered at 1-week post-
transplantation in immunesuppressed rats, we intend to compare the effect of 
hUCMS cells in immunesuppressed and non-immunesuppressed parkinsonian 
rats.  In conclusion, the hUMCS cells, a type of mesenchymal stem cells, may be 
therapeutically useful in treating central nervous system disorders such as PD. 
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Major conclusions and discussion 
Stem cells are not only drawing the attention of scientists, ethicists, policy 
makers and general public, but still maintain their place as one of the most 
promising yet controversial scientific discoveries of the 20th century.  Although 
there is some evidence of how these undifferentiated stem cells work, a more 
sophisticated research is on its way to authenticate and substantiate the 
applicability of stem cells for therapeutic purposes.  Various stem cells were 
shown to have therapeutic potential in a wide range of diseases, including 
neurodegenerative diseases such as Parkinson’s disease (PD).  To date, ESCs 
and NSCs have been used for cell-therapeutic purposes in animal models of PD, 
mostly to attempt to replace the damaged dopaminergic (DA) neurons.  Although 
there is some promising work demonstrating the efficacy of ESCs and NSCs in 
PD model animals (Bjorklund et al., 2002;Kim et al., 2002;Ourednik et al., 
2002;Pluchino et al., 2005), other associated limitations, such as pre- and post-
transplantation complications has lead researchers in this area to think about 
alternate sources of stem cells.  In addition, the relatively new neural 
regeneration/rescue strategies are exerting fundamental changes in the concepts 
of therapeutics for neurodegenerative diseases.  Post-natal and adult stem cells 
that bypass a number of limitations of ESCs and NSCs have been generating 
interest in the past few years.  While mesenchymal stem cells (MSCs) (Pittenger 
et al., 1999;Prockop et al., 2001;Woodbury et al., 2000)and multipotent adult 
progenitor cells (MAPCs) (Jiang et al., 2002;Reyes and Verfaillie, 2001;Schwartz 
et al., 2002) from bone marrow have created genuine interest in adult stem cells, 
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other sources of stem cells are constantly making news.  Here I describe a post-
natal or adult stem cell, derived from umbilical cord matrix (UCM), which is an 
inexhaustible source of mesenchymal-like stem cells that may have therapeutic 
importance in PD. 
 
Previously, it has been shown that pig UCMS cells express various stem cell 
characteristics and can be differentiated into neuron-like cells in vitro and in vivo 
(Mitchell et al., 2003;Weiss et al., 2003).  When transplanted into a normal rat 
brain, pUCMS cells expressed neuronal markers, such as NF-70 (Weiss et al., 
2003), a pig specific neurofilament protein.  Here, the safety and proliferative 
potential of pUCMS cells was evaluated in a 6-OHDA lesioned rat brain 
(Medicetty et al., 2004).  We have noticed that pUCMS cells engrafted and 
proliferated up to 8 weeks post-transplantation, where we observed a 7-8 fold 
increase in the number of graft cells.  In addition, graft cells expressing TH 
increased overtime from 1% at 2 weeks to 6% at 8 weeks following 
transplantation.  Moreover, there was no significant gross or histological 
evidence of immune rejection.  Although xenotransplantation could potentially 
provide an unlimited supply of transplantable tissues and organs for humans, the 
important risk factors that keep this technique out of the clinic are immune 
rejection, graft versus host disease (GVHD), cross-species transmission of 
undetected or unidentified animal infectious agents, and uncertain 
efficacy/viability.  It is known that replacement heart valves from pigs are used for 
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therapeutic purposes (Chen et al., 2003;Oxenham et al., 2003).  However, these 
therapeutic products have been chemically treated and are not living tissues, 
which distinguishes them from the viable organs or cells used in 
xenotransplantation.  As pUCMS cells were able to engraft, proliferate and 
differentiate in a rat brain without eliciting a frank immune response, they may be 
a potential xenogenic source of stem cells for therapeutic application in PD, with 
still having to address the safety concerns of xenotransplantation. 
 
Human UCM is a non-controversial and inexhaustible source of post-natal or 
adult stem cells.  The UCM may contain 1. Incompletely migrated EGCs, 2. 
HSCs dispersed in the surrounding connective tissue or 3. Mesenchymal-like 
connective tissue cells in the umbilical cord matrix that resembles embryonic 
mesenchyme.  The surface antigen profile and gene-expression profile of human 
UCMS cells closely resemble to that of mesenchymal stem cells (Weiss et al., 
2005).  The fact that hUCMS cells do not express the classic HSC markers, 
CD34 and CD45, tells that they may not be related to HSCs.  Although hUCMS 
cells express some primitive stem cell markers expressed by EGCs (Turnpenny 
et al., 2005), the morphology in culture and phenotype of the hUCMS cells do not 
resemble that of EGCs.  In addition, at this time it is unclear if hUMCS cells are 
pluripotent as EGCs (Pan et al., 2005;Park et al., 2004;Turnpenny et al., 2005).  
Recently, it has been shown that fetal MSCs have higher proliferative capacity 
and less lineage commitment than adult MSCs (Gotherstrom et al., 2005).  It is 
possible that the hUCMS are similar to that of fetal MSCs rather than adult 
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MSCs, as suggested by the source and gene expression, for example, 
preliminary data in our lab shows that hUCMS cells express HLA-G (data not 
shown), which is expressed by fetal MSCs, but not adult MSCs (Gotherstrom et 
al., 2005).   
 
One of the major concerns of stem cells in culture is the culture-induced genetic 
changes in the cells, which may be a big hurdle to pursue translational research 
and clinical trials.  It has been reported that 5 of the 11 human ESC lines in 
United States are genetically unstable (Maitra et al., 2005).  In this context, the 
hUCMS may have a major advantage over other stem cells as hUCMS cells can 
be harvested in relatively large numbers compared to other stem cells, which 
minimizes the culture-induced genetic changes that can occur in stem cells.  
Based on the length of the cord, 3 – 5 million cells can be extracted from each 
umbilical cord (Weiss et al., 2005).  To minimize the effect of the culture-induced 
changes in these experiments, we used the cells within 10 passages after 
extraction.  
 
Here, we noticed a dose-dependent behavioral improvement in PD model rats 
following hUCMS cell transplantation.  The low-density graft (1000 hUCMS cells) 
produced the best improvement, where more than 50% of the animals showed 
50-60% reduction and one animal showed 90% reduction in apomorphine-
induced rotatory behavior (Weiss et al., 2005).  Also, we observed a significant 
decrease in rotatory behavior in the animals that received medium-density graft 
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(2500 hUCMS cells).  Although some of the animals that received high-density 
graft (25,000 hUCMS cells) showed improvement in the rotatory behavior, as a 
group they were not significantly different from the control group that received 
vehicle (saline).  The non-PD model rats (animals that did not receive 6-OHDA) 
with or without low-density hUCMS cell transplants were not affected by 
apomorphine i.e. they did not show any apomorphine-induced rotatory behavior.  
The latter finding adds to the safety of hUCMS cells as transplantable cells as 
they do not seem to produce any physiological alterations (as indicated by 
apomorphine-induced rotations) in normal rats.   
 
However, we were able to recover hUCMS cells 2-days and 1-week post-
transplantation, but not at 6, 10 or 12 weeks, in non-immunesuppressed PD 
model rats.  This finding is completely in contrast to what we observed in non-
immunesuppressed rats that received pUCMS cell grafts.  As mentioned earlier, 
150 pUCMS cells survived and proliferated in 6-OHDA lesioned rat brain 
(Medicetty et al., 2004).  This may be due to 1. Non-primate cells including pig 
cells possess an enzyme -1, 3-galactosyl transferase (Alisky, 2004) that may 
help in evading the hyperacute rejection when transplanted into rats, increasing 
the chances of survival and proliferation, 2. Difference in the cell-phenotype 
owing to changes in culture media; pUCMS cells were grown in complete 
medium (see part II, methods section) (Medicetty et al., 2004;Weiss et al., 2003) 
where as hUCMS cells were expanded in defined medium (see part III, methods 
section) (Weiss et al., 2005).  Optimizing the culture conditions is a major 
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challenge in stem cell research.  Although, we had no problems expanding 
pUCMS cells in complete medium, the hUCMS cells did not seem to thrive well in 
complete medium.  Later, we started growing hUCMS cells in defined media 
(used for expanding MAPCs) (Jiang et al., 2002;Reyes and Verfaillie, 2001), and 
noticed that the cells were phenotypically stable up to 10 passages after 
extraction (Weiss et al., 2005).   
 
Previously, Bjorklund et al. showed that murine ESCs can differentiate into 
functional dopaminergic neurons in PD model rats; an important finding in this 
study is that low-density grafts were better than high-density grafts (Bjorklund et 
al., 2002).  Although this study was very promising, an important limitation in this 
highly cited publication is that, of the 25 animals treated, grafts did not survive in 
six, and five had grafts that developed into tumors or teratomas due to 
uncontrolled growth, and only the remaining 14 rats had cell grafts that survived 
and became dopaminergic.  In the above mentioned study, although the rats 
received immune suppression, 20% of the animals had tumors or teratomas, 
24% of the animals showed no graft survival and 56% of the animals responded 
to the graft.  Although we did not see a dramatic behavioral recovery (as seen 
with ESCs) (Bjorklund et al., 2002;Kim et al., 2002) in our experiments with 
hUCMS cells, we have noticed that approximately 50% of the animals respond to 
the graft.  Moreover, there are no tumors or teratomas observed in any of the 
transplanted animals, which is an important parameter to address the safety 
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concerns.  In addition, preliminary work in our lab suggests that hUCMS cells do 
not form tumors or teratomas in immunodeficient (SCID) mice (data not shown).   
 
Ron McKay's team at the National Institute of Neurological Disorders and Stroke 
(NINDS) showed that ESCs, which were genetically engineered and pre-
differentiated into dopaminergic neurons in vitro, were functional and useful in 
rescuing PD model rats (Kim et al., 2002).  Although, this group prevented 
tumorigenesis by pre-differentiating ESCs, the transgenic techniques have a long 
way to go before they can be approved for clinical trials in humans.   Also, there 
are other technical complications associated with transplanting pre-differentiated 
cells; for example, extensive network formation by the neurites extending from 
the differentiating cells may be subjected to mechanical damage during 
transplantation leading to cell death and in turn affecting the graft survival.  Both 
pig and human UCMS cells have shown to be able to differentiate into neuron-
like cells in culture.  However, we did not have an opportunity to transplant the 
pre-differentiated UCMS cells to compare the efficacy to that undifferentiated 
cells.  Recently, Fu et al. have reported that pre-differentiated human umbilical 
cord mesenchymal cells may be useful in halting the progression of disease in 
PD model rats (Fu et al., 2005).  However they have noticed that PD model rats 
transplanted with undifferentiated human umbilical cord mesenchymal cells 
deteriorated overtime similar to the controls that received PBS (Fu et al., 2005), 
which is in contrast to the behavioral improvement that we noticed after 
 170 
transplantation of 1000 and 2500 undifferentiated hUCMS cells.  The fact that we 
did not see any behavioral improvement in the PD model rats that received 
25000 cells may explain the finding reported by Fu et al., where they have 
transplanted 1x105 undifferentiated cells.  In future, we intend to conduct studies 
to look at the effect of pre-differentiation of UCMS cells in engraftment of the cells 
and promoting therapeutic benefit to PD models rats.   
 
Here, the hUCMS cells, when transplanted into PD model rats, showed 
improvement in the apomorphine-induced rotatory behavior.  However, we could 
not recover the graft cells at 6, 10 or 12 weeks post-transplantation.  In this 
context, we believe that hUCMS cells may be more useful to regenerate/rescue 
than they are to replace damaged DA neurons in PD.  We hypothesize that this 
behavioral improvement may be due to the trophic factors released by hUCMS 
cells.  Recently, it has been shown that umbilical cord blood cells (Borlongan et 
al., 2004;Newman et al., 2004) and bone marrow stromal cells (Chen et al., 
2001a;Chen et al., 2001b;Li et al., 2000) have neuroprotective effect that is 
mediated by trophic factors.  We have noticed that a majority of hUCMS cells in 
vitro express GDNF (Weiss et al., 2005), which is known to be a potent 
neurotrophic factor for DA cells.  Previous studies have shown that GDNF can 
rescue DA cells in culture as well as in PD animal models (Ding et al., 
2004;Arenas et al., 1995;Bjorklund et al., 1997;Kirik et al., 2000).  Currently, we 
are investigating this hypothesis by using an in vitro PD model, 6-OHDA treated 
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PC12 cells (Ha et al., 2003;Ryu et al., 2002).  In addition, the gene array shows 
that hUCMS cells make transcripts of other trophic factors such as, vascular 
endothelial growth factor (VEGF), fibroblast growth factor – 20 (FGF20) and 
ciliary neurotrophic factor (Weiss et al., 2005), which were previously shown to 
be neuroprotective (Greenberg and Jin, 2004a;Greenberg and Jin, 2004b;van 
der Walt et al., 2004;Cameron et al., 1998).  Also, we observed that the 
behavioral recovery in the PD model rats that received low-density hUCMS cell 
grafts correlates with the TH-positive DA cells in SN and VTA in the respective 
animals at 12 weeks following transplantation (Weiss et al., 2005).  Although we 
noticed a significant improvement in the rotatory behavior, we did not see a 
correlation with the TH-positive cells in the low-density 6-week survival and the 
medium-density grafts.  This may be attributed to the multiple host and graft 
factors affecting the efficacy of the graft.  With higher density graft, there may be 
increased host-reaction, which may in turn decrease the overall efficacy of the 
graft, suggesting the importance of the graft and host interaction in determining 
the efficacy of the graft.   
 
Although interaction between various parameters was shown to be an important 
indication of the graft efficacy in PD patients, a more comprehensive analysis of 
the patient and optimization of the graft is suggested to be essential for future PD 
studies (Lindvall and Bjorklund, 2004).  Here, we introduced a novel universal 
metric (Transplant or T – value) by including the multiple host and graft 
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parameters (see part IV, methods section), which can be used to asses the graft 
efficacy.  The parameters that are included in T-value, such as behavioral 
improvement (Dunnett et al., 1987;Nishimura et al., 2003;Olsson et al., 1995), 
host DA cells (Ourednik et al., 2002), graft outcome (Bjorklund et al., 2002;Kim et 
al., 2002) etc., have been considered separately by various researchers, but here 
we wanted to look at all the parameters simultaneously and generate a 
comprehensive measure of the improvement in the animals and efficacy of the 
graft.  We observed a positive correlation between T-value and behavioral 
recovery in all the experimental groups of PD model rats, which further 
corroborates the use of T-value to assess the graft efficacy.  In addition, this T-
value can be used to, 1. Analyze both replacement and rescue type of stem cell 
transplants, 2. Compare between different types of stem cell transplants and 3. 
Assess the efficacy of the cell grafts in other neural and non-neural disease 
conditions. 
 
Immune cells were implicated to play a critical role in various neurodegenerative 
disorders including PD (Block and Hong, 2005;Wu et al., 2005;Zhang et al., 
2005).  Thus, the immune modulatory capabilities of some stem cells may be 
useful to promote therapeutic benefit in PD.  Previous studies indicate that 
mesenchymal stem cells have immunosuppressive properties (Le et al., 
2004;Djouad et al., 2003).  Recently, it has been reported that mesenchymal 
stem cells may evade the allogenic host immune response by their 
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hypoimmunogenic properties, ability to prevent T-cell response by dendritic cell 
modulation, and by inducing a local immunosuppressive milieu (Ryan et al., 
2005).  As we did not notice any immune cells at the transplant site in the PD 
model rats that received UCMS transplant (Medicetty et al., 2004;Weiss et al., 
2005), it is possible that the graft cells may have evaded the host immune 
response by some immune modulatory mechanism.  Moreover, preliminary work 
in our lab suggests that hUCMS cells may have immunosuppressive properties 
(manuscript in preparation).  Also, it is known that cells at the feto-maternal 
interface in humans express HLA-G that has been shown to play a role in 
suppressing immune cells (Carosella et al., 2003;Rouas-Freiss et al., 
2003;Rouas-Freiss et al., 2000;Rouas-Freiss et al., 1999).  Preliminary studies in 
our lab suggest that hUCMS cells in vitro make transcripts of HLA-G (data not 
shown).  Ongoing studies in our lab would confirm and explain the 
immunosuppressive capabilities of hUCMS cells. 
 
I believe that replacement therapy by stem cells in PD is still in its initial stages 
and has a long way to go for clinical trials in human patients.  The prospects of 
using stem cells for replacement therapy in PD are complicated by the tasks that 
a donor replacement cell should complete to integrate into the host system i.e., a 
donor replacement cell should not only engraft in the host brain, but also should 
1. Evade the host immune response, 2. Differentiate and exhibit the required 
neural phenotype, 3. Extend neurites and make appropriate connections (form 
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synapses) with the other resident neurons and glia, 4. Produce appropriate 
neurotransmitters and conduct action potentials and 5. Survive and function for a 
long period.  Considering the above mentioned daunting tasks for a replacement 
cell, there is a better chance for stem cells being used to rescue, rather than to 
replace the damaged DA cells.  The rescue phenomenon is comparatively simple 
and is based on revitalizing the existing, but damaged host neural circuitry.  
Moreover, it is possible that the trophic and immune modulatory factors that are 
useful to rescue the damaged DA cells may cross the blood-brain barrier and 
thus may raise questions about the necessity of a brain transplant to treat PD.  
Based on the fact that approximately 90% of the PD patients are in the 5th and 6th 
decades of their life, avoiding a brain transplant would add an enormous benefit 
for the normal health of the patient.  Although it is yet to be proven, it would be 
ideal to have a stem cell that can be injected through intravenous route and can 
produce trophic and immune modulatory factors that can cross the blood-brain 
barrier and rescue the damaged DA cells.  
 
The question remains whether any of these stem cells work in the PD patients; 
can the animal model results be directly related to a human patient? Recent trials 
showed that patients with PD did not benefit from receiving fetal neural tissue 
transplants; indeed, some patients experienced jerky abnormal involuntary 
movements, known as dyskinesias (Check, 2003).  Moreover, it has been shown 
that L-DOPA, which is used for symptomatic treatment in PD, induces 
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dyskinesias that are a major concern in managing PD patients (Obeso et al., 
2000b;Obeso et al., 2000a).  Although the primary cause of dyskinesia remains 
to be established, studies in animal models are beginning to unravel the cellular 
and molecular details of this movement disorder.  Previous studies have shown 
that drug-induced dyskinesia is associated with changes in gene expression in 
DA projection areas in the brain (Cenci et al., 1998) and depends on the 
topography of DA denervation with in the projection areas (Winkler et al., 2002).  
These drug and graft induced dyskinesias may pose a significant concern by 
affecting the behavioral analysis, particularly the drug-induced rotatory behavior, 
in the PD animal model studies.  We speculate, based on the ongoing studies in 
our lab, that the drug-induced rotatory behavior may be affected by dyskinesias 
(data not shown), which may lead to ambiguity in interpretation of the data.  It is 
possible that the control animals may show a decrease in the drug-induced 
rotations due to dyskinesias.  However, a dyskinesia scoring system has been 
recently introduced that evaluates various abnormal involuntary movements, thus 
providing a tool to assess the reliability of these animal models (Winkler et al., 
2002).  In future, we intend to follow-up the dyskinetic animals, if there are any, 
by using the dyskinesia scoring system and if necessary, modify the behavioral 
tests accordingly; as there are other valid tests to evaluate PD model animals 
with out using any drugs (Olsson et al., 1995;Dunnett et al., 1987).   
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In conclusion, the UCM is a source of post-natal or adult stem cells.  Pig UCMS 
cells engraft and proliferate following transplantation into a lesioned-rat brain, 
where a subset of the graft cells express neuronal markers (Medicetty et al., 
2004).  Human UCMS cells are non-controversial and can be extracted in large 
numbers, and phenotypically resemble mesenchymal stem cells (Weiss et al., 
2005).  When transplanted in PD model rats, hUCMS cells show a dose-
dependent improvement in the rotatory behavior, and thus may have therapeutic 
applications in PD.   Further investigation is underway to unveil the mechanism 
by which hUCMS cells produce this improvement in PD model rats.   
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